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Engineering of polyketide biosynthetic pathways for bioactive molecules 
by 
Siyuan Wang, Doctor of Philosophy 
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Major Professor: Jixun Zhan 
Department: Biological Engineering 
 
Polyketides are a large group of structurally diverse natural products that have 
shown a variety of biological activities. These molecules are synthesized by polyketide 
synthases (PKSs). PKSs are classified into three types based on their sequence, primary 
structure, and catalytic mechanism. Because of the bioactivities of polyketide natural 
products, this study is focused on the engineering of PKS pathways for efficient 
production of useful bioactive molecules or structural modification to create new 
molecules for drug development. 
 
One goal of this research is to create an efficient method to produce 
pharmaceutically important molecules. Seven biosynthetic genes from plants and 
bacteria were used to establish a variety of complete biosynthetic pathways in 




phenylpropanoid acids, three bioactive natural stilbenoids, and three natural 
curcuminoids. A curcumin analog dicafferolmethane was synthesized by removing a 
methyltransferase from the curcumin biosynthetic pathway. Furthermore, introduction 
of a fungal flavin-dependent halogenase into the resveratrol biosynthetic pathway 
yielded a novel chlorinated molecule 2-chloro-resveratrol. This demonstrated that 
biosynthetic enzymes from different sources can be recombined like legos to make 
various plant natural products, which is more efficient (2-3 days) than traditional 
extraction from plants (months to years). Phenylalanine ammonia-lyase (PAL) is a key 
enzyme involved in the first biosynthetic step of some plant phenylpropanoids. Based 
on the biosynthetic pathway of curcuminoids, a novel and efficient visible reporter 
assay was established for screening of phenylalanine ammonia-lyase (PAL) efficiency 
in Escherichia coli. 
 
The other goal of this research is to characterize and engineer natural product 
biosynthetic pathways for new bioactive molecules. The biosynthetic gene cluster of 
the antibacterial compound dutomycin was discovered from Streptomyces minoensis 
NRRL B-5482 through genome sequencing. Confirmation of the involvement of this 
gene cluster in dutomycin biosynthesis and creation of a series of new molecules were 
successfully conducted by rationally modifying the biosynthetic pathway. More 




antibacterial activity against Staphylococcus aureus and methicillin-resistant 
Staphylococcus aureus.       
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Department: Biological Engineering 
 
This study is focused on engineering of natural product biosynthetic pathways for 
efficient production of pharmaceutically important molecules or generation of new 
bioactive molecules for drug development. 
 
Plant natural products are an important source of therapeutics, such as paclitaxel 
(anticancer) and artemisinin (anti-malarial). Production of plant natural products relies 
on conventional plant cultivation and solvent extraction, which is time-consuming and 
cost-ineffective. This work built a biosynthetic platform in Escherichia coli using 
seven biosynthetic genes from plants and bacteria, which were used to make valuable 
compounds such as the strong antioxidant resveratrol and anti-inflammatory agent 




to produce four phenylpropanoid acids (cinnamic acid, p-coumaric acid, caffeic acid, 
and ferulic acid), three bioactive natural stilbenoids (resveratrol, piceatannol and 
pinosylvin), and three natural curcuminoids (curcumin, bisdemethoxycurcumin and 
dicinnamoylmethane). “Unnatural” natural products including dicafferolmethane and 
2-chloro-resveratrol were also generated by modifying the existing pathways. Based 
on the color of curcuminoids, a novel and efficient visible reporter assay was 
established for screening of phenylalanine ammonia-lyase (PAL), an enzyme involved 
in the first biosynthetic step of many plant natural products.  
 
Actinomycetes are a group of bacteria well-known for the production of 
antibiotics. A strong antibacterial agent, dutomycin, was discovered from 
Streptomyces minoensis NRRL B-5482. Through genome sequencing and targeted 
gene disruption, a type II polyketide biosynthetic gene cluster was found to be 
responsible for the assembly of dutomycin. Several key enzymes in the pathway were 
functionally characterized and a series of new analogs were generated, including a 
new compound with more promising antibacterial activity.   
 
Metabolic engineering of natural product biosynthetic pathways showed its 
promise for creating and producing valuable compounds with chemical diversity for 
drug discovery. This research has biosynthesized 17 valuable molecules with 




platforms and technical basis for further engineering polyketide biosynthetic pathways 
to produce valuable bioactive molecules and generate novel analogs for bioactivity 
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CHAPTER 1 INTRODUCTION 
1.1 Background 
Polyketides are a class of secondary metabolites produced by bacteria, fungi, and 
plants, such as rapamycin, erythromycin, and lovastatin. They draw more and more 
attention from scientists and engineers in the biomedical field due to their biological 
activities, potential for drug discovery, and commercial value. These natural products 
have displayed a variety of biological activities, such as antibacterial, anticancer, 
antifungal, antiparasitic, coccidiostats, and immunosuppressive properties. 
Engineering of polyketide biosynthetic pathways allows the generation of novel 
compounds that are difficult to be synthesized by other methods. Type I PKSs are 
multifunctional enzymes that are arranged into modules with different catalytic 
domains. Ketosynthase (KS), acyl transferase (AT), and acyl carrier protein (ACP) are 
the essential domains for polyketide chain elongation. Other functional domains like 
ketoreductase (KR), enoyl reductase (ER), dehydratase (DH), and methyltransferase 
(MT) may be involved according to different polyketide structures. Type I PKSs are 
found in bacteria, fungi, and other organisms.  
 
Type II PKSs are aggregates of small discrete proteins with different 
mono-functions.  This group of PKSs is essentially involved in the biosynthesis of 
bacterial aromatic polyketides [1], such as oxytetracycline [2] and pradimicin [3-5]. 




and ACP. The nascent polyketide chain synthesized by the minimal PKS is subjected 
to further modifications by KR, cyclase (CYC), methyltransferase (MT) and 
glycosyltransferase (GT). The polyketide backbone is generated by condensation of 
an acyl starter unit and multiple malonyl-CoA extender units. In addition to 
malonyl-CoA that is a common starter and extender unit, other CoA substrates such as 
fatty acyl-CoAs and benzoyl-CoA also act as starter units in aromatic polyketide 
biosynthesis [1-5]. This feature enables the structural diversity and unique biological 
activities of aromatic polyketides. Based on the polyphenolic ring system and their 
biosynthetic pathways, bacterial aromatic polyketides can be classified into different 
subfamilies, such as anthracyclines, angucyclines, aureolic acids, tetracyclines, 
tetracenomycins, pradimicin-type polyphenols, and benzoisochromanequinones [6]. 
 
Anthracyclines are ranked among the most effective anticancer drugs that have 
been developed [7]. The first two anthracyclines discovered were named rhodomycin 
and cinerubicin [8]. A few years later, daunorubicin (trade name Daunomycin) was 
isolated from Streptomyces peucetius in the 1950s by Farmitalia Research 
Laboratories as well [9]. Anthracyclines inhibit DNA and RNA synthesis and 
topoisomerase II enzyme to prevent the rapidly growth of cells [10-12]. Also, they 
can generate free oxygen radicals to damage the DNA, protein and cell membranes 
[10]. Hence, several anthracyclines, including daunorubicin, epirubicin, doxorubicin 




anthracycline polyketides in the nature is streptomycetes, which are well-known 
producers of structurally and functionally diverse molecules [13,14]. 
 
Dutomycin (Fig. 1) is an anthracycline that was first isolated from soil bacteria 
Streptomyces sp. 1725 from a soil sample collected in Yunnan, China [15]. This 
compound showed strong in vitro cytotoxic activity against leukemia P388 [15]. 
Dutomycin consists of a tetracyclic anthraquinone core structure and associated sugar 
moieties, which is similar to other anthracycline antibiotics such as polyketomycin, 
daunorubicin, epirubicin, doxorubicin and aclacinomycin. All of these compounds are 
generated by the corresponding producers through a type II polyketide biosynthetic 
pathway [16]. Dutomycin is structurally similar to polyketomycin from Streptomyces 
sp. MK277-AF1, which showed activity against Gram-positive bacteria including the 
multi-drug-resistant strain methicillin-resistant Staphylococcus aureus (MRSA) [17].  
 
Fig. 1 The structure of dutomycin. 
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chain extension, and cyclization to form polyketide products. They are small dimeric 
proteins (40-45 kDa) that catalyze iterative condensation reactions with malonyl-CoA. 
In recent years, type III PKSs, especially plant type III PKSs, drew more and more 
attentions since their applications in medicine and agriculture. Plant type III PKSs 
have been extensively studied since the first type III PKS was discovered in the 1970s 
[18]. The major compounds produced by plant type III PKSs are flavonoids, 
stilbenoids and curcuminoids. 
 
Stilbenoids (Fig. 2), containing a C6-C2-C6 structure, are a class of plant 
secondary metabolites which are often involved in injury control when the plant is 
threatened by bacteria or fungi [19]. These molecules have shown a variety of 
biological properties, such as antioxidant, antibacterial [20], antifungal [21], 
anticancer, anti-inflammatory [22] and anti-aging activities [23]. Their biosynthesis 
has been studied in plants [24], yeast and mammal cells [25]. Stilbene synthase (STS) 
is a type III PKS that plays an essential role in the biosynthesis of stilbenoids. In 2003, 
Becker J. et al. first reported the reconstruction of a biosynthetic pathway consisting 
of 4-coumaroyl coenzyme A ligase (4CL) and STS in S. cerevisiae to produce 
resveratrol [26]. When 5 mM p-courmaric acid was supplemented, resveratrol was 
produced by engineered strains of S. cerevisiae and E. coli at 6 mg/l and 16 mg/l, 
respectively [27]. Also, Watts  et al. reconstituted the same biosynthetic pathway 




then. For instance, Zhang et al. used a fusion protein of 4CL and STS to increase the 
yield of resveratrol in S. cerevisiae by about 20 folds [25]. Coincidentally, Lim et al. 
finally improved the titer to 2.3 g/l resveratrol with this precursor pathway by testing 
different STS genes from various plant species and optimizing the expression 












Fig. 2 Structures of three major natural stilbenoids. 
Stilbenoid biosynthesis uses cinnamoyl-CoA or p-coumaroyl-CoA as the starter 
unit, meaning that it shares the early biosynthetic steps as in the biosynthesis of 
flavonoids and isoflavonoids described above. To achieve the total biosynthesis of 
stilbenoids, tyrosine ammonia-lyase and phenylalanine ammonia-lyase (TAL/PAL) 
and 4CL need to be added into the pathway, which will allow in situ supply of the 
desired CoA starter. Wang et al. reported a stepwise increase of resveratrol 
biosynthesis in S. cerevisiae to 3.44 mg/l from the amino acids in 2011 [30]. On the 
other hand, it is possible to modify the structure of stilbenoids through the 
introduction of some foreign enzymes to generate new derivatives. For example, a 
3-O-glucosyltransferase (3-O-GT) was introduced to the resveratrol biosynthetic 





Curcuminoids are another group of plant phenylpropanoid metabolites, which 
consist of two aromatic rings connected with a 7 carbon chain with different chemical 
groups [32]. A representative member of this family is curcumin (Fig. 3). It is a 
natural plant polyphenol with yellow color, and was isolated from the herb Curcuma 
longa with other two derivatives demethoxycurcumin and bisdemethoxycurcumin 
[33]. Curcuminoids are used as food spice (curry) and food coloring agent (E100). In 
addition, they are the major bioactive components in turmeric that has been used in 
traditional medicine for centuries. Curcuminoids are well-known for their anti-tumor, 
anti-oxidant, anti-inflammatory, anti-allergic, and hepatoprotective activities [34-39]. 
The polyketide biosynthetic pathways of curcuminoids in different plants have been 
investigated. Kiat et al. studied the biosynthetic pathway of curcuminoids in turmeric 
using 
13
C-labeled precursors [40]. To gain a better understanding of curcuminoid 
biosynthesis, two novel type III PKSs, diketide-CoA synthase (DCS) and curcumin 
synthase (CURS), were cloned from C. longa and subjected to enzymatic studies. It 
was revealed that DCS catalyzes the condensation of feruloyl-CoA and malonyl-CoA 
to form feruloyldiketide-CoA, which is subsequently used by CURS to form curcumin 
[41]. Two additional CURSs were discovered in the C. longa and named as CURS2 
and CURS3. These two CURSs were found to have different substrate preference. 
CURS2 synthesizes curcumin and demethoxycurcumin, while CURS3 has the ability 








Fig. 3 The structure of curcumin. 
There is another way to generate curcuminoids in nature. Curcuminoid synthase 
(CUS) was identified from Oryza sativa. Unlike the pathway in C. longa that requires 
collaborative actions of two type III PKSs, this single PKS has the ability to 
synthesize curcuminoids from malonyl-CoA and aromatic CoA esters such as 
4-coumaroyl-CoA, cinnamoyl-CoA, and feruloyl-CoA [43]. The broad substrate 
spectrum makes it possible to synthesize derivatives with different functional groups 
and improved water solubility or bioactivity. Three curcuminoids including 
dicinnamoylmethane, bisdemethoxycurcumin and cinnamoyl-p-coumaroylmethane 
were produced by the engineered E. coli strain [44]. Seventeen curcumin analogs 
were produced in E. coli through precursor-directed biosynthesis [45].  
1.2 Objectives 
The main goal of my doctoral dissertation research was to engineer natural 
product biosynthetic pathways for de novo synthesis of existing or new bioactive 
molecules, including phenylpropanoid acids, stilbenoids, and curcuminoids. 
Additionally, I developed an in vivo reporter assay for phenylalanine ammonia-lyase. 




dutomycin via genome sequencing and gene disruption, and generated a promising 
antibacterial agent. 
Specific objectives include: 
1. Construct a platform for de novo biosynthesis of various plant natural 
products and their novel derivatives in E. coli. 
2. Establish an in vivo reporter assay for phenylalanine ammonia-lyase. 
3. Investigate the biosynthetic pathway of dutomycin and generate new 
antibacterial analogs. 
1.3 A guide to the dissertation 
This dissertation includes five chapters. Chapter 2 and Chapter 3 describe the 
engineering of a variety of plant natural product biosynthetic pathways into 
Escherichia coli to generate bioactive molecules, including phenylpropanoid acids, 
stilbenoids, and curcuminoids [46]. In Chapter 4, an in vivo novel and efficient visible 
reporter assay was established for screening of PAL efficiency in Escherichia coli, 
based on the color of a curcuminoid synthesized through this platform [47]. Finally, 
Chapter 5 focuses on the study of an unknown type II polyketide biosynthetic pathway 
that is responsible for the synthesis of dutomycin in Streptomyces. New compounds 
were generated through rational modification of the pathway [48]. Several scientific 




engineering, microorganism culturing, protein expression, natural products isolation, 
NMR and MS for structure determination, DNA sequence analysis, and others.  
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CHAPTER 2   ENGINEERED PRODUCTION OF HYDROXYCINNAMIC ACIDS 
AND STILBENOIDS IN E. COLI* 
ABSTRACT 
Plants produce a variety of natural products with promising biological activities, 
such as phenylpropanoids and stilbenoids. While these molecules are naturally 
assembled through dedicated plant metabolic pathways, combinatorial biosynthesis 
has become an attractive tool to generate desired molecules. In this chapter, we 
demonstrated that biosynthetic enzymes from different sources can be recombined 
like legos to make various molecules. Seven biosynthetic genes from plants and 
bacteria were used to establish a variety of complete biosynthetic pathways in 
Escherichia coli to make valuable compounds. Different combinations of these 
biosynthetic bricks were made to design rationally various natural product pathways, 
yielding four phenylpropanoid acids (cinnamic acid, p-coumaric acid, caffeic acid, 
and ferulic acid), three bioactive natural stilbenoids (resveratrol, piceatannol and 
pinosylvin). 
2.1 Introduction 
Plants are a major producer of structurally diverse and medicinally important 
molecules, such as resveratrol and curcumin. Resveratrol belongs to the family of 




stilbenoids. These natural products are present in several plants such as grapes and 
peanuts, but are not widely distributed in other common food sources. Interestingly, 
the slight structural differences of stilbenoids may lead to different functions and 
applications. For instance, resveratrol is widely used in the clinical and neutraceutical 
fields due to its protection effects against a series of diseases, such as Parkinson’s, 
cancer, and heart disease. It also reduces serum lipids and possesses other beneficial 
effects. Recent studies demonstrated that resveratrol can significantly prolong 
life-span in non-vertebrate model organisms and short-lived vertebrates [1, 2]. 
Piceatannol is a hydroxylated derivative of resveratrol. It naturally occurs in various 
plants, including grapes, berries, passion fruit, white tea, and Japanese knotweed. It is 
also a metabolic product of resveratrol in the human body. This compound has shown 
strong anticancer, anti-aethrogenic, antioxidant, anti-inflammatory, antimicrobial and 
estrogenic activities, which is even more potent than resveratrol [3, 4]. Like 
resveratrol, piceatannol is also a bioactive component in wine, although at a much 
lower concentration [4]. Pinsoylin is a dehydroxylated derivative of resveratrol and 
present in the heartwood of Pinaceae. This compound is a pre-infectious fungitoxin 
and protects the wood from fungal infections. It showed stronger antifungal activity 
against Candida albicans and Saccharomyces cerevisiae than resveratrol [5]. These 





In this chapter, we established a library of biosynthetic bricks with five 
biosynthetic enzymes from plant, bacterial and fungal sources. These include 
phenylalanine ammonia-lyase (PAL), tyrosine ammonia-lyase (TAL), and 
4-coumarate: CoA ligase (4CL), stilbene synthase (STS), 4-coumarate 3-hydroxylase 
(C3H). These enzymes were expressed or co-expressed in E. coli BL21 (DE3) in 
different combinations, resulting in the production of four phenylpropanoid acids 
including cinnamic acid, p-coumaric acid, caffeic acid, and ferulic acid). Introduction 
of the corresponding PKS led to the total biosynthesis of three bioactive natural 
stilbenoids (resveratrol, piceatannol and pinosylvin). 
2.2 Materials and methods 
2.2.1 General method 
Products were analyzed and purified on an Agilent 1200 HPLC instrument. 
ESI-MS spectra were obtained on an Agilent 6130 quadrupole LC-MS. NMR spectra 
were recorded on a JEOL NMR instrument (300 MHz for 
1
H NMR). The chemical 
shift (δ) values are given in parts per million (ppm). The coupling constants (J values) 
are reported in Hertz (Hz). 
2.2.2 Strains, media and culture conditions 
E. coli XL1-Blue was used for routine cloning and plasmid propagation. It was 
grown at 37°C on LB agar plates or in liquid LB medium supplemented with 




μg/ml; chloramphenicol, 25μg/ml). E. coli BL21 (DE3) was used for protein 
expression and compound biosynthesis. E. coli BL21 (DE3) was grown at 37°C on 
LB agar plates or in liquid LB medium supplemented with appropriate antibiotics. 
Enzymes were expressed in E. coli BL21 (DE3) at 28°C.  
2.2.3 Gene manipulation and plasmids construction 
Restriction enzymes, Phusion® High-Fidelity DNA polymerase, and T4 DNA 
ligase were purchased from New England Biolabs (Ipswich, MA, USA). CloneJET™ 
PCR Cloning Kit was purchased from Fermentas (Glen Burnie, MD, USA), and the 
pET28a, pCDFDuet-1 and pACYCDuet-1 vectors were purchased from Novagen 
(Madison, WI, USA). The 4cl cDNA (GenBank accession number U18675) was 
amplified from pUC-4CL1 (provided by Dr. Claudia Schmidt-Dannert, University of 
Minnesota). The sts gene (GenBank accession number AB027606) was amplified 
from pUC-STS (obtained from Addgene). The tal gene (GenBank accession number 
ABC88669) was cloned from the S. espanaensis NRRL 15764 genomic DNA. The 
c3h gene (GenBank accession number DQ357071) was amplified from S. espanaensis 
NRRL 15764 genomic DNA. The comt gene (GenBank accession number 166420) 
was cloned from iGEM part BBa_I742107 (provided by Dr. Charles Miller, Utah 
State University). The primers are shown in Table 1. These four PCR products were 
gel purified and ligated into the pJET1.2 cloning vector to yield pSW52, pSW63, 
pSW87, pSW96 and pSW98 respectively (Table 2). The genes were confirmed by 
















* Restriction sites are italicized and the start/stop codons are shown in bold. 
After sequencing, the sts gene was excised from pSW63 via NheI/BamHI and 
ligated to pET28a between the same sites to form pSW65. The tal gene was excised 
from pSW87 via NcoI/EcoRI and introduced to the pCDFDuet-1 vector to yield 
pSW95. The c3h gene was then excised from pSW96 and ligated to pSW95 between 
the NdeI and XhoI sites to yield pSW97. The comt gene was cut from pSW98 with 





Table 2. Plasmids used in Chapters 2 and 3. 
Plasmid Description Reference 
pUC-4cl1 The 4cl cDNA from A. thaliana (Watts et al., 2006) 
pET16b-cus The cus cDNA from O. sativa (Katsuyama et al., 2008) 
pUC-sts The sts cDNA from A. hypogaea Purchased from Addgene 
pZJ54 rdc2 in pET28a (Zeng and Zhan, 2010) 
pSW24 cus in pET28a (Wang et al., 2013) 
pSW54 4cl in pACYCDuet-1 (Wang et al., 2013) 
pSW56 pal and 4cl in pACYCDuet-1 (Wang et al., 2013) 
pSW60 pal in pACYCDuet-1 (Wang et al., 2013) 
pSW63 sts in pJET1.2 this work 
pSW65 sts in pET28a this work 
pSW87 tal in pJET1.2 this work 
pSW95 tal in pCDFDuet-1 this work 
pSW96 c3h in pJET1.2 this work 
pSW97 c3h and tal in pCDFDuet-1 this work 
pSW98 comt in pJET1.2 this work 
pSW99 
pSW117 
comt and 4cl in pACYCDuet-1 
comt in pACYCDuet-1 
this work 
this work 
pSW121 sts and tal in pCDFDuet-1 this work 
2.2.4 Biosynthesis of hydroxycinnamic acids and stilbenoids in E. coli 
Corresponding plasmids were electroporated into E. coli BL21 (DE3). The 
resulting strains were grown in 50 ml of LB medium supplemented with appropriate 




was added at a final concentration of 200 µM, and the induced culture was maintained 
at 28°C with shaking at 250 rpm for an additional 5 h. Substrates (glucose and 
L-phenylalanine or L-tyrosine) were added, and the culture was incubated under the 
same conditions for an additional 48 h. For biotransformation, resveratrol or ferulic 
acid was added as the substrate. After fermentation, 1 ml of the culture was sampled 
and centrifuged at 14,000 rpm for 10 min. 100 µl of the supernatant was then 
analyzed by LC-MS. 
2.2.5 HPLC analysis of the biosynthesized compounds 
Analysis of p-coumaric acid, caffeic acid, and ferulic acid was conducted on an 
Agilent 1200 HPLC system with an Agilent Eclipse XDB-C18 column (5 μm, 250 
mm × 4.6 mm). The samples were eluted with acetonitrile-water (15:85, v/v) for 25 
min under 300 nm at a flow rate of 1 ml/min. Cinnamic acid was analyzed on the 
same instrument, eluted with acetonitrile-water (30:70, v/v) for 25 min at 300 nm at a 
flow rate of 1 ml/min. Analysis of stilbenoids were conducted on the same equipment, 
eluted with a gradient of acetonitrile-water (20:80, v/v for 18 min, 20:80, v/v to 50:50 
v/v from 18 min to 30 min, 50:50 v/v from 30 min to 40 min) at a flow rate of 1 
ml/min. The products were detected at 330 nm. The titers of all the biosynthetic 
compounds were calculated based on the standard curves of the purified compounds 
or commercial samples.  




The biosynthesized compounds were characterized by LC-MS and a comparison 
with authentic samples. Resveratrol was also isolated from the fermentation broth and 
subjected to NMR analysis (Appendix B). 
2.3 Results 
2.3.1 Engineered biosynthesis of phenylpropanoid acids in E. coli 
We have cloned a total of eight genes from various sources, including pal from 
Trifolium pretense (plant), tal from Saccharothrix espanaensis NRRL 15764 
(bacterium), 4cl from Arabidopsis thaliana (plant), c3h from S. espanaensis NRRL 
15764 (bacterium), comt from Medicago sativa (plant), sts from Arachis hypogaea 
(plant). These genes constitute a tool box for combinatorial biosynthesis of a variety 
of molecules. 
 
Using a biosynthetic approach, we have successfully produced four 
phenylpropanoid acids including cinnamic acid, p-coumaric acid, caffeic acid, and 
ferulic acid in E. coli BL21(DE3) in high yields when 3 mM L-phenylalanine and 
L-tyrosine was supplied. The compounds were characterized based on a comparison 
of the ESI-MS (Fig. 4), and retention time with those of authentic samples. As shown 
in Fig. 1, expression of PAL from T. pretense in E. coli yielded cinnamic acid as a 
dominant product (Fig 5 trace i) at 241.3 ± 2.8 mg/l. Similarly, expression of TAL 




coli at 160.5 ± 2.1 mg/l (Fig 5 trace ii). Co-expression of TAL with C3H from S. 
espanaensis NRRL 15764, which hydroxylates p-coumaric acid at C-3', led to the 
production of caffeic acid at 70.0 ± 0.9 mg/l (Fig 5 trace iii). Further addition of 




Fig. 4 ESI-MS analysis of hydroxycinnamic acids production.   a. ESI-MS (-) 
spectrum of p-coumaric acid production from L-tyrosine; b. ESI-MS (-) spectrum of 
















































Fig. 5 Engineered biosynthesis of phenylpropanoid acids in E. coli. (i) HPLC analysis 
of the biosynthesis of cinnamic acid by E. coli/PAL; (ii) HPLC analysis of the 
biosynthesis of p-coumaric acid by E. coli/TAL; (iii) HPLC analysis of the 
biosynthesis of caffeic acid by E. coli/TAL-C3H; (iv) HPLC analysis of the 
biosynthesis of ferulic acid by E. coli/TAL-C3H-COMT. Mobile phase for trace i was 
30% acetonitrile– water, and 15% acetonitrile–water was used for traces ii–iv. The 
products were detected at 300 nm. 
 












2.3.2 Engineered biosynthesis of resveratrol in E. coli 
Three enzymes including TAL, 4CL and STS are required to synthesize 
resveratrol from the amino acid precursor. To this end, we cloned these three genes 
into three expression vectors, including pET28a, pACYCDuet-1 and pCDFDuet-1, to 
yield three expression plasmids, pSW54 pSW65 and pSW95 (Table 2). These 
plasmids were co-expressed in E.coli BL21 (DE3). The engineered strain was grown 
in LB medium. 0.6 mM L-tyrosine and 4 g/l glucose were added into the induced 
culture assupplemented amino acid substrate and carbon source. As shown in Fig. 6, 
LC-MS analysis revealed that a major product at 26.5 min was produced, which was 
identified as resveratrol based on the ESI-MS (Fig. 6b), UV (Fig. 6c), and 
1
H NMR 
spectra (Appendix B).  
 
To optimize the production of resveratrol in the engineered E. coli, L-tyrosine 
and glucose were fed individually or together into the induced culture. As shown in 
Fig. 7a, when no nutrients were supplemented, the trace (trace ii) is same as that of 
the blank control E. coli BL21 (DE3) harboring the blank vectors (trace i). When 
glucose was added, resveratrol was produced by the engineered strain that harbors the 
corresponding biosynthetic genes. Thus, glucose is necessary for resveratrol 
biosynthesis, which provides the cells with a premium carbon source to supply the 
required polyketide biosynthetic precursor malonyl-CoA. By contrast, when 




supply of malonyl-CoA. When both glucose and L-tyrosine were supplied, the 
production of resveratrol was significantly improved. We next determined the optimal 
concentration of L-tyrosine and glucose. As shown in Fig. 7b, the titer of resveratrol 
increased with the increased concentrations of the substrates. The titer reached a 
maximum when 0.6 mM L-tyrosine and 4 g/l glucose were added. Further increase in 
the concentrations of these substrates did not lead to any improvements of resveratrol 
biosynthesis. However, the intermediate p-coumaric acid started to accumulate. The 
highest titer of resveratrol was determined to be 114.4 ± 3.5 mg/l. 
 
Fig. 6 LC-MS analysis of resveratrol production. a. the HPLC trace of resveratrol 
production from Tyrosine; b. ESI-MS (+) spectrum of resveratrol production from 
tyrosine; c. UV spectrum of resveratrol production from tyrosine. 
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Fig. 7 Condition optimization for resveratrol production. a. different substrates 
condition for resveratrol production ( i: Tyr, glucose feeding; ii: glucose feeding; iii: 
Tyr feeding; iv: none feeding control; v: blank vectors in BL21(DE3) with Tyr, 
glucose feeding control.); b. different substrates concentration (i: 0 mM Tyr, 0g/l 
glucose; ii: 0.3 mM Tyr, 2g/l glucose; iii: 0.6 mM Tyr, 4 g/l glucose; iv 1.5 mM Tyr, 
10 g/l glucose; v: 3mM Tyr, 20 g/l glucose). 
2.3.3 Engineered biosynthesis of piceatannol and pinosylvin in E.coli 
Using the library of biosynthetic bricks constructed above, we next made two 
resveratrol analogs. Piceatannol is a natural resveratrol analog with an additional 
phenolic hydroxyl group at C-3'. To make this compound, we first employed a 
biotransformation approach using a C3H from S. espanaensis NRRL 15764. This 
enzyme was used to create caffeic acid and ferulic acid above, which indicated that it 
can introduce a hydroxyl group to p-coumaric acid at C-3'. However, it was unclear 
















hydroxylate resveratrol at C-3', C3H was then individually expressed in E. coli BL21 
(DE3). The IPTG-induced broth was incubated with resveratrol. LC-MS revealed that 
a major product at 15.5 min was generated by the engineered E. coli BL21 (DE3) 
strain, together with the substrate resveratrol at 26.5 min (trace ii, Fig. 8). The product 
was characterized as piceatannol by a comparison of the retention time, ESI-MS 
(Appendix B) spectra with those of the commercial standard of piceatannol. 
Conversion of resveratrol to piceatannol revealed the broad substrate specificity of 
this C3H. The titer of piceatannol from this biotransformation process was 65.4 ± 1.0 
mg/l. 
 
Total biosynthesis of piceatannol has never been reported. We next constructed a 
biosynthetic pathway of this natural product by introducing C3H into the resveratrol 
biosynthetic pathway. To this end, TAL, 4CL, C3H and STS were co-expressed in E. 
coli BL21 (DE3). LC-MS analysis revealed that a major product was synthesized 
from L-tyrosine. The retention time (trace iii, Fig. 8), UV and ESI-MS of this product 
were consistent with those of the authentic sample of piceatannol, confirming that a 
complete biosynthetic pathway of piceatannol was successfully constructed in E. coli. 
The titer of piceatannol from this total biosynthetic pathway was determined to be 





Pinosylvin is another natural resveratrol analog that lacks a hydroxyl group at C-4. 
The biosynthesis of this compound has never been studied. Based on its structure, we 
proposed that the biosynthetic pathway of this molecule is similar to that of 
resveratrol. To synthesize this compound, L-phenylalanine should be used as the 
starting amino acid precursor. Thus，we need a PAL to convert L-phenylalanine to 
cinnamic acid. However, successful biosynthesis of pinosylvin also requires the 
ability of 4CL and STS to accept “unnatural” substrates, meaning that 4CL can ligate 
cinnamic acid with CoA to yield cinnamoyl-CoA and STS can take cinnamoyl-CoA 
as the starter unit. To test this, we co-expressed PAL, 4CL and STS in E. coli BL21 
(DE3). LC-MS analysis revealed that a major metabolite at 34.5 min was produced 
(trace iv, Fig. 8). The ESI-MS spectrum showed an ion peak [M-H]
-
 at m/z 211 
(Appendix B), suggesting that the molecular weight of this compound is 212. The UV 
spectrum (Appendix B) and retention time of this product were same as those of the 
commercial standard of pinosylvin. Therefore, we were able to for the first time 
establish the complete pinosylvin biosynthetic pathway in E. coli.  The titer of 
pinosylvin was determined to be 13.3 ± 0.8 mg/l. 
2.4 Conclusion 
In this chapter, we established a library of biosynthetic bricks with five 
biosynthetic enzymes from different sources, including PAL, TAL, 4CL, STS and 
C3H. These enzymes were expressed or co-expressed in E. coli BL21 (DE3) in 




(cinnamic acid, p-coumaric acid, caffeic acid, and ferulic acid). Introduction of the 
corresponding PKS led to the total biosynthesis of three bioactive natural stilbenoids 
(resveratrol, piceatannol and pinosylvin). The results from this chapter provided 
important platforms and technical basis for further engineering polyketide biosynthetic 
pathways for producing valuable bioactive molecules. 
 
Fig. 8 Engineered biosynthesis of resveratrol analogs in E. coli.(i) HPLC analysis of 
the biosynthesis of resveratrol by E. coli/TAL-4CL-STS; (ii) Conversion of 




HPLC analysis of the biosynthesis of piceatannol by E. coli/TAL-4CL-STS-C3H; (iv) 
HPLC analysis of the biosynthesis of pinosylvin by E. coli/PAL-4CL-STS.The 
products were detected at 330 nm. 
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CHAPTER 3   ENGINEERED PRODUCTION OF CURCUMINOID AND TWO 
UNNATURAL ANALOGS IN E.COLI* 
ABSTRACT 
Curcuminoid, which is produced specifically by the expression of curcuminoid 
synthase (CUS) gene, has long been used as traditional Asian medicines because of its 
reported activities on anti-tumor, antioxidant and hepatoprotective. Hence, CUS gene 
is an attractive target for metabolic engineering. In this chapter, we modified the 
library of biosynthetic bricks mentioned in Chapter 2 with eight biosynthetic enzymes 
from plant, bacterial and fungal sources, which resulted in producing three natural 
curcuminoids (curcumin, bisdemethoxycurcumin and dicinnamoylmethane). 
Remarkably, a curcumin analog dicafferolmethane was synthesized by removing a 
methyltransferase from the curcumin biosynthetic pathway. Furthermore, introduction 
of a fungal flavin-dependent halogenase into the resveratrol biosynthetic pathway 
yielded a novel chlorinated molecule 2-chloro-resveratrol. This work thus provided a 
novel and efficient biosynthetic approach to create various bioactive molecules. 
Further expansion of the library of the biosynthetic bricks will provide a resource for 
rational design of various phenylpropanoids via the combinatorial biosynthesis 





Curcuminoids are another family of plant polyphenols, exemplified by curcumin, 
a major component in turmeric. Turmeric has long been used as a food spice (curry) 
and complementary and alternative medicine (CAM) in Asia [1-4]. These compounds 
possess various bioactivities and can be used for the treatment of different diseases 
such as allergy, asthma, cancer and Alzheimer's disease, while providing prevention 
against oxidative damage in normal cells [5-9].  
 
The above-mentioned natural products are assembled through well designed plant 
metabolic pathways. These compounds are traditionally extracted from the 
corresponding producing plants. Given the long growth period of plants, this is neither 
efficient nor cost-effective. Development of synthetic biology and metabolic 
engineering techniques provides a great opportunity to synthesize these molecules in 
microorganisms. Some progresses have been made in engineered biosynthesis of plant 
natural products such as coumarins [10, 11] in microorganisms. Resveratrol has also 
been produced in the yeast Saccharomyces cerevisiae, although the yield was only 6 
mg/l [12, 13]. However, there is no report on total biosynthesis of piceatannol or 
pinsoylin. The biosynthesis of curcumin has also been studied. Two type III 
polyketide synthases (PKSs), diketide-CoA synthase (DCS) and curcumin synthase 
(CURS), are involved in the biosynthesis of curcuminoids in the herb Curcuma longa 
[14]. Compared to the collaborative actions of two type III PKSs in C. longa, one 




synthesize curcuminoids. With supplementation of different carboxylate precursors, 
curcumin and several analogs were synthesized in E. coli [15]. However, total 
biosynthesis of curcumin from an amino acid precursor has not been reported.  
 
In this chapter, we modified the library of biosynthetic bricks mentioned in 
chapter 2 with eight biosynthetic enzymes from plant, bacterial and fungal sources. 
These include phenylalanine ammonia-lyase (PAL), tyrosine ammonia-lyase (TAL), 
4-coumarate:CoA ligase (4CL), stilbene synthase (STS), CUS, 4-coumarate 
3-hydroxylase (C3H), caffeic acid 3-O-methyltransferase (COMT), and a 
flavin-dependent halogenase Rdc2. Introduction of the corresponding PKS led to 
three natural curcuminoids (curcumin, bisdemethoxycurcumin and 
dicinnamoylmethane). Remarkably, we also generated two novel molecules by 
constructing a new curcuminoid biosynthetic pathway and adding a fungal halogenase 
to the resveratrol pathway, respectively. This work thus demonstrated a highly 
efficient combinatorial biosynthesis approach to creating various plant 
phenylpropanoids in E. coli. 
3.2 Materials and methods 
3.2.1 General method 
Products were analyzed and purified on an Agilent 1200 HPLC instrument. 




were recorded on a JEOL NMR instrument (300 MHz for 
1
H NMR). The chemical 
shift (δ) values are given in parts per million (ppm). The coupling constants (J values) 
are reported in Hertz (Hz). 
3.2.2 Strains, media and culture conditions 
E. coli XL1-Blue was used for routine cloning and plasmid propagation. It was 
grown at 37°C on LB agar plates or in liquid LB medium supplemented with 
appropriate antibiotics (ampicillin, 50 μg/ml; kanamycin, 50 μg/ml; streptomycin, 50 
μg/ml; chloramphenicol, 25μg/ml). E. coli BL21 (DE3) was used for protein 
expression and compound biosynthesis. E. coli BL21 (DE3) was grown at 37°C on 
LB agar plates or in liquid LB medium supplemented with appropriate antibiotics. 
Enzymes were expressed in E. coli BL21 (DE3) at 28°C.  
3.2.3 Gene manipulation and plasmids construction 
Based on the work in chapter 2, the comt gene was cut from pSW98 with 
NotI/PstI and ligated into pSW54 between the same sites, yielding pSW99. The sts 
was introduced to pSW95 to form pSW121 via the MefI/XhoI sites. Construction of 
pSW24, pSW54, pSW56, pSW60 and pZJ54 has been reported in our previous studies 
[16, 17]. 
3.2.4 Biosynthesis of hydroxycinnamic acids and stilbenoids in E. coli 
Corresponding plasmids were electroporated into E. coli BL21 (DE3). The 




antibiotic(s) at 37C with shaking at 250 rpm. Once the OD600 reached 0.4-0.6, IPTG 
was added at a final concentration of 200 µM, and the induced culture was maintained 
at 28°C with shaking at 250 rpm for an additional 5 h. Substrates (glucose and 
L-phenylalanine or L-tyrosine) were added, and the culture was incubated under the 
same conditions for an additional 48 h. For biotransformation, resveratrol or ferulic 
acid was added as the substrate. After fermentation, 1 ml of the culture was sampled 
and centrifuged at 14,000 rpm for 10 min. 100 µl of the supernatant was then 
analyzed by LC-MS. 
3.2.5 HPLC analysis of the biosynthesized compounds 
Analysis of stilbenoids were conducted on the same equipment, eluted with a 
gradient of acetonitrile-water (20:80, v/v for 18 min, 20:80, v/v to 50:50 v/v from 18 
min to 30 min, 50:50 v/v from 30 min to 40 min) at a flow rate of 1 ml/min. The 
products were detected at 330 nm. Curcuminoids were analyzed on the same 
equipment, eluted with a gradient of acetonitrile-water (from 10:90, v/v to 100:0, v/v 
over 30 min) at a flow rate of 1 ml/min. The products were detected at 420 nm. The 
titers of all the biosynthetic compounds were calculated based on the standard curves 
of the purified compounds or commercial samples.  
3.2.6 Identification of the biosynthetic compounds 
The biosynthesized compounds were characterized by LC-MS and a comparison 




also isolated from the fermentation broth and subjected to NMR analysis (Appendix 
C). 
3.3 Results 
3.3.1 Engineered biosynthesis of curcumin and two analogs in E. coli 
The biosynthesis of curcuminoids has been previously studied. Curcuminoids 
including bisdemethoxycurcumin, dicinnamoylmethane and cinnamoyl-p- 
coumaroylmethane have been synthesized in E. coli that harbors PAL from the yeast 
Rhodotorula rubra, 4CL from Lithospermum erythrorhizon and CUS from O. sativa, 
in the presence of L-phenylalanine or L-tyrosine. Curcumin was also synthesized by 
CUS and 4CL in E. coli when ferulic acid was supplied as a substrate. However, total 
biosynthesis of curcumin from the amino acid precursor has not been achieved. We 
have co-expressed PAL from T. pretense, 4CL from A. thaliana and CUS from O. 
sativa in E. coli to generate the curcumin analog dicinnamoylmethane in our previous 
study (trace i, Fig. 9) [16]. This confirmed that CUS was functional in our system and 
it is possible to make curcuminoids directly from the amino acid precursor. We first 
replaced PAL with TAL in the dicinnamolymethane biosynthetic pathway. 
Accordingly, co-expression of TAL, 4CL and CUS yielded a major product at 17.7 
min (trace ii, Fig.9). The ion peak [M-H]
-
 at m/z 307.0 in the ESI-MS spectrum (Fig. 
10b) indicated the molecular weight of this product is 308. The retention time and UV 




bisdemethoxycurcumin. Thus, we were able to construct a complete biosynthetic 
pathway for bisdemethoxycurcumin, which co-exists with curcumin in turmeric. This 
compound is a minor bioactive component of turmeric and a common impurity in the 
commercial product of curcumin. The titer of bisdemethoxycurcumin was determined 
to be 28.9 ± 1.0 mg/l. Our method thus provides an efficient way to produce this 
minor constituent of turmeric.  
  
Fig. 9 Engineered biosynthesis of curcuminoids in E. coli. (i) HPLC analysis of the 
biosynthesis of dicinnamoylmethane by E. coli/PAL-4CL-CUS; (ii) HPLC analysis of 
the biosynthesis of bisdemethoxycurcumin by E. coli/TAL-4CL-CUS; (iii) HPLC 




HPLC analysis of the total biosynthesis of curcumin from L-tyrosine by E. coli/ 
TAL-C3H-COMT-4CL-CUS.The products were detected at 420 nm. 
We next attempted to establish a complete biosynthetic pathway of curcumin in E. 
coli. We first tested whether 4CL from A. thaliana can ligate ferulic acid with CoA to 
yield feruloyl-CoA, the starter unit for curcumin biosynthesis. The cus and 4cl genes 
were respectively ligated to two expression vectors and co-expressed in E. coli BL21 
(DE3). Ferulic acid was supplemented into the IPTG-induced culture of the 
engineered strain. HPLC analysis revealed a major product at 18.5 min (trace iii, Fig. 
9). The molecular weight of the peak was determined to be 368 based on the 
quasimolecular ion peak [M-H]
-
 at m/z 367.0 in the ESI-MS spectrum (Fig. 10d). The 
UV spectrum of this product (Fig. 10c) was same as that of the authentic sample of 
curcumin. The compound was isolated from the broth and subjected to 1H NMR 
analysis (Appendix C), which confirmed that this product was curcumin. Thus, we 
proposed that 4CL from A. thaliana could convert ferulic acid to feruloyl-CoA in our 
expression system. Because we have made ferulic acid using TAL, C3H and COMT 
in E. coli, we propose that co-expression of these enzymes with 4CL and CUS should 
yield curcumin. The five genes were then ligated to three expression vectors to yield 
pSW24, pSW97 and pSW99 (Table 2). Co-expression of these plasmids in E. coli 
cells yielded curcumin (trace iv, Fig. 9). Therefore, a total biosynthetic pathway of 
curcumin was established in E. coli. The titer of this compound was determined to be 






Fig. 10  LC-MS analyses of natural curcuminiods production. a. UV spectrum of 
bisdemethoxycurcumin production from tyrosine; b. ESI-MS (-) spectrum of 
bisdemethoxycurcumin production from Tyrosine; c. UV spectrum of curcumin 
production from tyrosine; d. ESI-MS (-) spectrum of curcumin production from 
tyrosine. 
3.3.2 Engineered biosynthesis of novel resveratrol and curcumin analogs in E. coli 
With the library of eight biosynthetic genes, we further expanded their uses for 
combinatorial biosynthesis of novel molecules. Because halogenated compounds 

































account for a quarter of the current drugs or those in the development pipeline, it will 
be of significant interest to generate halogenated molecules for bioactivity screening. 
To achieve this goal, we selected a fungal flavin-dependent halogenase Rdc2, which 
was characterized in our previous studies as the dedicated halogenase in radicicol 
biosynthesis [17]. This enzyme has broad-substrate specificity. As shown in trace i of 
Fig. 11, co-expression of TAL, 4CL, STS and Rdc2 in E. coli BL21 (DE3) yielded a 
new product at 30 min in addition to resveratrol. The molecular weight of this new 
product was found to be 262 based on the ion peaks [M-H]
-
 at m/z 261 and 263 (3:1) 
and [M+Cl]
-
 at m/z 297 (Fig. 12a). The ratio of 3:1 is a characteristic isotope pattern 
of monochlorinated molecule. Compared to resveratrol, a bathochromic shift was 
observed in the UV spectrum of the product (Fig. 12b). Thus, the product was 
deduced to be a chlorinated derivative of resveratrol. This compound was then 
purified and subjected to 1H NMR analysis (Appendix), based on which it was 
identified as 2-chloro-resveratrol. The titer was determined to be 7.0 ± 0.3 mg/l.  
 
Commercially available curcumin product prepared from the herb Curcuma longa 
usually contains 77% curcumin, 17% demethoxycurcumin and 3% 
bisdemethoxycurcumin. However, no naturally occurring demethylated derivatives of 
curcumin are known. Given the poor water solubility of curcumin, demethylation of 
curcumin may represent an effective way to increase its polarity and water solubility. 




CUS so that a new demethylated curcumin analog can be generated with 
caffeoyl-CoA as the starter unit. These enzymes were co-expressed in E. coli BL21 
(DE3). HPLC analysis revealed a dominant product at 14.8 min (trace ii, Fig. 11). Its 
molecular weight was determined to be 340 based on the [M-H]
-
 ion peak at m/z 
339.1 (Fig. 12c). It was 28 mass units less than curcumin, suggesting that it is a 
didemethylated analog of curcumin. This was supported by the UV spectrum of this 
compound, which is similar to that of curcumin. The product was then purified and 
subjected to NMR analysis (Appendix C), based on which it was characterized as 
dicafferolmethane. [18] The titer was determined to be 2.8 ± 0.5 mg/l.  
 
Fig. 11 Engineered biosynthesis of novel resveratrol and curcumin analogs in E. coli. 




coli/TAL-4CL-STS- Rdc2 at 330nm; (ii) HPLC analysis of the biosynthesis of 
dicaffeoylmethane by E. coli/TAL-C3H-4CL-CUS at 420 nm. 
 
Fig. 12 LC-MS analyses of unnatural polyphenols production.a. ESI-MS (-) spectrum 
of halogenated resveratrol production from tyrosine; b. comparison of UV spectrum of 
halogenated resveratrol and resveratrol; c. ESI-MS (-) spectrum of dicafferolmethane 
production from tyrosine. 
3.4 Conclusion 
Natural products are a major source of new drugs. Numerous structures have been 
discovered from Nature, such as the well-known anticancer drug paclitaxel. The 
molecules are assembled through well designed biosynthetic pathways that consist of 
a series of collaborative biosynthetic enzymes. Plant natural products are traditionally 
extracted from the producing species. This process is inefficient since it takes long 
time from seeding to harvest. Although some natural product biosynthetic pathways 
from plants have been reported, direct engineering of these pathways in plants are 
technically challenging and time-consuming. Recent development in genome 





























artificial biosynthetic pathways in a heterologous host to generate plant natural 
products or novel structures. This work systematically demonstrated that a variety of 
biosynthetic pathways (Fig. 13) can be constructed based on eight biosynthetic 
enzymes to yield a number of biologically relevant molecules.    
  
We made a small library of biosynthetic genes that were from different sources 
(plant, bacterial and fungal). Using a multiple-vector approach, these biosynthetic 
bricks can be combined in different ways to yield desired molecules. In 
phenylpropanoid biosynthesis, amino acids are first converted to various carboxylic 
acid precursors, which serve as the starter units for the following polyketide chain 
elongation. These phenylpropanoid acids include cinnamic acid, p-coumaric acid, 
caffeic acid, and ferulic acid. Some of these acids such as caffeic acid have also 
shown antioxidant activity [3]. In addition, these acids also show inhibitory activity 
on intestinal alpha-glucosidase activity, which delays the digestion of starch and 
disaccharides to absorbable monosaccharides and may help reduce postprandial 
hyperglycemia [19]. These compounds are synthesized from amino acids including 
L-phenylalanine and L-tyrosine. The simplest biosynthetic pathways constructed in 
this work were the production of p-coumaric acid (Fig. 13A, 160.5 ± 2.1 mg/l) and 
cinnamic acid (Fig. 13B, 241.3 ± 2.8 mg/l), which were synthesized from L-tyrosine 
by TAL and L-phenylalanine by PAL, respectively. While both enzymes showed high 




more efficiently than TAL in E. coli. p-Courmaic acid can be hydroxylated by C3H, 
as revealed by the production of caffeic acid at 70.0 ± 0.9 mg/l by E. coli/TAL-C3H 
(Fig. 13A). The titer of the final product decreased when an additional step was 
introduced to the pathway. This result was further supported by the production of 
ferulic acid (Fig. 13A) by E. coli/TAL-C3H-COMT at 28.8 ± 0.4 mg/l when the third 
enzyme COMT was introduced. Increasing the expression level of enzymes for the 
late steps may help increase the overall efficiency of such multi-step biosynthetic 
pathways.  
 
With the pool of the eight biosynthetic enzymes, more complex biosynthetic 
pathways were constructed to generate a series of bioactive plant natural products. 
While resveratrol biosynthesis has been reconstituted in E. coli in previous studies, 
the total biosynthesis of piceatannol and pinosylvin was achieved for the first time in 
this work. The biosynthetic pathway of pinosylvin was rationally designed based on 
its structural similarity to resveratrol, and successfully established by taking 
advantage of the substrate flexibility of both 4CL and STS. The biosynthesis of 
piceatannol was constituted by the introduction of a C3H into the resveratrol 
biosynthetic pathway. This C3H represents a flexible hydroxylase with broad 
substrate specificity. It not only hydroxylates p-coumaric acid at C-3' to yield caffeic 
acid, but also converts resveratrol to piceatannol by the hydroxylation at the same 




coli can also hydroxylate resveratrol at the same position [20]. Production of 
pinosylvin and piceatannol provides in E. coli an efficient way to produce these plant 
natural products. More complex biosynthetic pathways were constructed using the 
pool of biosynthetic enzymes to yield a series of curcuminoids. Collaborative actions 
of five enzymes including TAL, 4CL, C3H, COMT and CUS in E. coli resulted in the 
total biosynthesis of the pharmaceutically important molecule curcumin.  
 
We also demonstrated the feasibility of rational design of new molecules, either 
by removal or addition of an enzyme from a particular biosynthetic pathway. For 
example, removal of COMT from the curcumin biosynthetic pathway leaves the 8- 
and 8'-OH unmethylated, leading to the production of the curcumin analog 
dicafferolmethane. When a halogenase Rdc2 was added to the resveratrol biosynthetic 
pathway, a novel chlorinated analog of resveratrol was produced. This molecule has 
been previously chemically synthesized [18]. However, chemical preparation of 
chlorinated is limited by the lack of selection. In this constructed pathway, Rdc2 can 
specifically introduce a chlorine atom at C-2, further indicating that this enzyme has 
broad substrate specificity. 2-Chloro-resveratrol has shown stronger antioxidant and 
antimicrobial activity than resveratrol [18].    
 
In summary, we used a simple set of eight biosynthetic enzymes to achieve the 




produced by varying the combinations of these enzymes. For example, co-expression 
of TAL, 4CL, C3H, STS and Rdc2 in E. coli is expected to generate 
2-chloro-piceatannol. Functional expression of the biosynthetic enzymes in E. coli is 
required, while substrate flexibility of these enzymes is preferred as this will 
significantly increase the number of possible pathways that can be constructed. 
Further expansion of this library of biosynthetic “legos” will yield a huge resource to 
produce pharmaceutically important molecules in a fast-growing host or synthesize 
novel compounds for bioactivity screening. 
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Fig. 13 Combinatorial biosynthesis of plant natural products and their analogs in E. 
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CHAPTER 4   DESIGN AND APPLICATION OF AN IN VIVO REPORTER 
ASSAY FOR PHENYLALANINE AMMONIA-LYASE * 
ABSTRACT 
Phenylalanine ammonia-lyase (PAL) is an important enzyme that links primary 
metabolism to secondary metabolism. Its efficiency is often a critical factor that 
affects the overall flux of a related metabolic pathway, the titer of the final products, 
and the efficacy of PAL-based therapies. Thus, PAL is a common target for metabolic 
engineering and it is of significant interest to screen efficient PALs for industrial and 
medical applications. In this study, a novel and efficient visible reporter assay for 
screening of PAL efficiency in E. coli was established based on a plant type III 
polyketide biosynthetic pathway. The candidate PALs were co-expressed with a 
4-coumarate:CoA ligase 4CL1 from Arabidopsis thaliana and curcuminoid synthase 
(CUS) from Oryza sativa in E. coli BL21(DE3) to form a dicinnamoylmethane 
biosynthetic pathway. Taking advantage of the yellow color of the product, a 
microplate-based assay was designed to measure the titer of dicinnamoylmethane, 
which was validated by HPLC analysis. The different titers of the product reflect the 
overall performance (expression and enzymatic efficiency) of the individual PALs in 
E. coli. Using this system, we have screened three PALs (PAL1, PAL3 and PAL4) 
from Trifolium pratense, among which PAL1 showed the best performance in E. coli. 




of dicinnamoylmethane at a high level of 0.36g/l. Supplement of 
2-fluoro-phenylalanine yielded two fluorinated dicinnamoylmethane derivatives, 6, 
6’-difluoro-dicinnamoylmethane and 6-fluoro-dicinnamoylmethane, of which the 
latter is a new curcuminoid. 
4.1 Introduction  
Phenylalanine ammonia-lyase (PAL, EC 4.3.1.5) catalyzes the conversion of 
phenylalanine (Phe) to trans-cinnamic acid and ammonia through deamination. It is 
considered to be an essential linker between the primary metabolism and secondary 
metabolism [1, 2] as it is involved in both amino acid metabolism and natural product 
biosynthetic pathways. Because of its importance in different metabolic pathways, 
PAL has gained considerable significance in medical, industrial, and biotechnological 
applications [3]. Since its discovery in 1961[4], PAL has been extensively 
investigated. Many PAL genes have been discovered from plants and microorganisms 
and some of the structures have been solved [5, 6].  
 
PAL is a potential agent in the treatment of phenylketonuria, an autosomal 
recessive genetic disorder that results in an inability to metabolize Phe and elevated 
levels of this amino acid in the bloodstream, which can cause severe mental 
retardation. Oral or subcutaneous administration of PAL led to substantial lowering of 
plasma and brain Phe levels [7-9]. With further improvement of the stability, this 




used in industry to produce L-Phe from trans-cinnamic acid by taking advantage of 
the reversal of the physiological reaction [10]. A PAL from Rhodotorula glutinis can 
directly convert trans-cinnamic acid methyl ester to L-Phe methyl ester, which 
eliminates the need for chemical esterification of L-Phe with methanol in aspeartame 
synthesis [11]. PAL is also frequently observed in secondary metabolic pathways that 
lead to the formation of various natural products such as enterocin in the marine 
bacterium Streptomyces maritimus [12] and phenylpropanoids in plants [13] including 
flavonoids, isoflavonoids, coumarins, stilbenes, hydroxycinnamic acids, lignin, and 
other phenolic compounds. In addition to serving as regulatory or signaling molecules 
in plants [14], many of these natural products have also displayed promising 
biological activities such as antioxidant, antimicrobial and anti-inflammatory 
properties. PAL catalyzes the first biosynthetic step of phenylpropanoid products and 
plays a key regulatory role in controlling the biosynthesis of these natural products. Its 
efficiency is important for carbon flux into these pathways and directly influences the 
yields of the final products. Thus, PAL has become a critical metabolic engineering 
target for many natural product biosynthetic pathways. 
 
Curcuminoids are a group of plant phenylpropanoid natural products, exemplified 
by curcumin, and have long been used as a traditional Asian medicine because of their 
anti-tumor, antioxidant, anti-inflammatory, anti-allergy and hepatoprotective activities 




various foods. Recently, curcuminoids have been found to be synthesized by type III 
polyketide synthases (PKSs) in plants. Two type III PKSs, diketide-CoA synthase 
(DCS) and curcumin synthase (CURS), are involved in the biosynthesis of 
curcuminoids in the herb Curcuma longa. DCS takes feruloyl-CoA and malonyl-CoA 
to synthesize feruloyldiketide-CoA, which is further converted into curcumin by 
CURS [25]. When other substrates such as 4-coumaryol-CoA are taken, different 
curcuminoids can be formed. In contrast to the collaborative actions of two type III 
PKSs in C. longa, an individual type III PKS from Oryza sativa, curcuminoid 
synthase (CUS), was found to synthesize curcuminoids from aromatic CoA starters 
and malonyl-CoA. CUS has been functionally expressed in Escherichia coli. Its 
co-expression with PAL from Rhodotorula rubra and 4-coumarate: CoA ligase (4CL) 
from Lithospermum erythrorhizon has led to the production of plant-specific 
curcuminoids in E. coli [26]. The engineered strain was also utilized to produce 
unnatural curcuminoids by providing a variety of carboxylate precursors [27].  
 
In spite of the importance of PAL, there is no efficient screening assay for this 
type of enzyme. The yellow color makes curcuminoids potential reporter molecules. 
In this study, we established a novel and efficient visible screening assay for efficient 
PALs in an E. coli system based on the curcuminoids biosynthetic pathway. The 
overall performance of a PAL is reflected in the titer of dicinnamoylmethane (1, Fig. 




Using this system, we have compared the efficiency of three PALs from Trifolium 
pratense and found that PAL1 showed the highest efficiency in E. coli. The 
collaborative work of PAL1 with 4CL1 from Arabidopsis thaliana and CUS from O. 
sativa led to the high-yield production of 1 in E. coli. Supplement of 2-fluoro-L-Phe 
into the fermentation broth yielded two fluorinated dicinnamoylmethane derivatives, 
6-fluoro-dicinnamoylmethane (2, Fig. 14) and 6,6'-difluoro-dicinnamoylmethane (3, 
Fig. 14). 2 is a new compound. 
 
Fig. 14 Curcuminoids (1-3) synthesized in E. coli. 1 was synthesized from L-Phe. 
4.2 Materials and methods  
4.2.1 General method 
Products were analyzed and purified on an Agilent 1200 HPLC instrument. 
ESI-MS spectra were acquired on an Agilent 6130 quadrupole LC-MS in the positive 
mode. NMR spectra were recorded in acetone-d6 on a JEOL NMR instrument (300 
MHz for 1H NMR and 75 MHz for 13C NMR). The chemical shift (δ) values are 




Hertz (Hz). The titers of 1 were analyzed on a SpectraMax® 190 Absorbance Plate 
Reader (Molecular Devices, CA, USA) and an Agilent 1200 HPLC system. 
4.2.2 Bacterial strains and materials 
E. coli XL1-Blue was utilized for routine cloning and plasmid propagation. E. 
coli BL21 (DE3) was used for protein expression and the designed reporter assay. All 
E. coli strains were grown at 37 °C on LB agar plates or in liquid LB medium 
supplemented with appropriate antibiotics (ampicillin, 50µg/ml; kanamycin, 50µg/ml; 
chloramphenicol, 25µg/ml; Gold Biotechnology, MO, USA). Restriction enzymes, 
Phusion® High-Fidelity DNA polymerase, and T4 DNA ligase were purchased from 
New England Biolabs (Ipswich, MA, USA). CloneJET™ PCR Cloning Kit was from 
Fermentas (Glen Burnie, MD, USA), and the pET28a and pACYCDuet-1 vectors 
were purchased from Novagen (Madison, WI, USA). The plasmids including 
pMLS252-PAL1, pMLS252-PAL3 and pMLS252-PAL4 that contain the cDNAs of 
PALs were gifts from Dr. Mike Sullivan from USDA. The plasmids pUC-4CL1 
(containing the cDNA of 4CL1 from A. thaliana) and pET16b-CUS (containing the 
cDNA of CUS from O. sativa) were respectively provided by Dr. Claudia 
Schmidt-Dannert at the University of Minnesota and Dr. Nobutaka Funa at the 
University of Shizuoka, Japan. 




The cDNAs encoding PAL1 (GenBank accession number DQ073809), PAL3 
(GenBank accession number DQ073808) and PAL4 (GenBank accession number 
DQ073811) were amplified with Phusion® High-Fidelity DNA polymerase from 
pMLS252-PAL1, pMLS252-PAL3 and pMLS252-PAL4, respectively. A 30-cycle 
polymerase chain reaction (PCR) program (60 s at 98 °C, 60 s at 68 °C and 150 s at 
72 °C) was used. The 4CL1 cDNA (GenBank accession number U18675) was 
amplified from pUC-4CL1 using a 30-cycle PCR program (60 s at 98 °C, 60 s at 
62 °C and 135 s at 72 °C). The primers are shown in Table 3. These four PCR 
products were gel-purified and ligated into the pJET1.2 cloning vector to yield 
pSW48, pSW49, pSW50 and pSW52 (Table 4). The genes were confirmed by 
digestion checks and sequencing.   
 
The CUS gene (GenBank accession number Q8LIL0) was excised from 
pET16b-CUS with NdeI and BamHI and ligated into pET28a between the same sites, 
yielding pSW24. The 4CL1 gene was excised from pSW52 with NdeI and XhoI and 
ligated into pACYCDuet-1 between the same sites, yielding pSW54. The PAL1, 
PAL3 and PAL4 genes were excised with PstI and NotI from pSW48, pSW49 and 
pSW50, respectively, and ligated to pSW54 between the same sites to yield pSW56, 

























Table 4. Plasmids used in Chapter 4. 
Plasmid Description  Reference 
pMLS252-pal1 The intron-free PAL1gene from T. 
pratense  
(Sullivan 2009) 
pMLS252-pal3 The intron-free PAL3 gene from T. 
pratense 
(Sullivan 2009) 
pMLS252- pal4 The intron-free PAL4 gene from T. 
pratense 
(Sullivan 2009) 
pUC-4cl1 The 4CL1 cDNA from A. thaliana (Watts et al. 2006) 
pET16b-cus The CUS cDNA from O. sativa (Katsuyama et al. 
2007) 
pSW24 CUS in pET28a  this work 
pSW48 PAL1 in pJET1.2  this work 
pSW49 PAL3 in pJET1.2  this work 
pSW50 PAL4 in pJET1.2  this work 
pSW52 4CL1 in pJET1.2  this work 
pSW54 4CL1 in pACYCDuet-1  this work 
pSW56 PAL1 and 4CL1 in pACYCDuet-1   this work 
pSW57 PAL3 and 4CL1 in pACYCDuet-1 this work 
pSW58 PAL4 and 4CL1 in pACYCDuet-1 this work 
4.2.4 Dicinnamoylmethane production in E. coli 
A typical fermentation procedure is as follows. Engineered E. coli BL21 (DE3) 
strains were precultured overnight at 37 
o




50 µg/ml kanamycin and 25 µg/ml chloramphenicol. The preculture was transferred 
into 50 ml of LB medium with the same antibiotics and cultured at 37 
o
C until the 
OD600 reached 0.4~0.6. IPTG was then added at a final concentration of 1 mM and the 
induced culture was maintained at 25 
o
C with shaking at 250 rpm for an additional 5 h. 
After that, 3 mM L-Phe, 40 g/l glucose and 25 g/l CaCO3 were added, and the culture 
was incubated at 25 
o
C for an additional 60 h. The fermentation broth was harvested 
by centrifugation at 4,000 rpm for 10 min. The supernatant was adjusted to pH 3.0 
with 6 M HCl and extracted with an equal volume of ethyl acetate. The cells were 
extracted with 10 ml of methanol by sonication. The extracts were concentrated by 
solvent evaporation and subjected to product analysis.  
4.2.5 Microplate-based assay for dicinnamoylmethane biosynthesis in E. coli 
To purify 1 for structural characterization and quantification of its production in 
the engineered E. coli strains, the extract of 100 ml of the fermentation broth of E. 
coli BL21 (DE3)/pSW24+pSW56 was separated on a silica gel 60 open column. The 
column was successively washed with a gradient of hexane/acetone (1:0, 9:1, 3:1, 1:1, 
and 0:1, v/v). The fraction eluted by hexane/acetone (9:1) was found to contain 1 and 
further separated on an Agilent 1200 HPLC using a SUPELOD SupelcosilTM 
LC-PAH column (5 um, 250 mm × 10 mm), eluted with acetonitrile-water (70:30, v/v) 
at a flow rate of 3 ml/min for 45 min. The peak at 30 min was collected, yielding 12 
mg of 1 in pure form. The compound was structurally characterized based on its 





Dicinnamoylmethane (1): yellow powder. 
1
H NMR (300 MHz, acetone-d6):  
7.71 (4H, d, J = 5.9 Hz, H-6, H-6', H-10, and H-10'), 7.70 (2H, d, J = 15.1 Hz, H-4 
and H-4'), 7.44 (6H, m, H-7, H-7', H-8, H-8', H-9, and H-9'), 6.89 (2H, d, J = 15.8 Hz, 
H-3 and H-3'), 6.14 (1H, s, H-1). 13C NMR (75 MHz, acetone-d6):  184.4 (C-2 and 
C-2'), 141.2 (C-4 and C-4'), 136.1 (C-5 and C-5'), 131.1 (C-8 and C-8'), 129.9 (C-7, 
C-7', C-9, and C-9'), 129.1 (C-6, C-6', C-10, and C-10'), 125.2 (C-3 and C-3'), 102.6 
(C-1). 
 
The purified compound was dissolved in methanol and prepared as different 
concentrations by a serial dilution. The solutions of 1 was distributed into the wells in 
a 96-well UV-plate (Corning, NY, USA) and measured on a SpectraMax® 190 
Absorbance Plate Reader at 390 nm to get the standard curve. For time course 
analysis, the fermentation broths were sampled at 12, 24, 36, 48, 60, and 72 h, 
respectively. The samples (1 ml each) were extracted as described above and the dried 
extracts were re-dissolved in 1 ml of methanol, from which 200 µl of each extract was 
subjected to titer analysis on the SpectraMax® 190 Absorbance Plate Reader.  
4.2.6 HPLC analysis of dicinnamoylmethane biosynthesis in E. coli 
A standard curve of 1 was established by injecting different amounts of the 
purified compound into HPLC and correlating the peak areas to the amounts.  




Eclipse XDB-C18 column (5 um, 250 mm × 4.6 mm). The samples were eluted with 
acetonitrile-water (70:30, v/v) at a flow rate of 1 ml/min for 30 min, and the product 
was detected at 390 nm. For time course analysis, 200 µl of the same samples used for 
the microplate-based assay were analyzed by HPLC.  
4.2.7 Quantitative real-time PCR analysis of PAL expression in E. coli 
For quantitative real time-PCR (qRT-PCR) analysis of the expression of PAL1, 
PAL3 and PAL4, total RNA was extracted from E. coli BL21(DE3)/pSW24+pSW56, 
E. coli BL21(DE3)/pSW24+pSW57 and E. coli BL21(DE3)/pSW24+pSW58, 
respectively, using a Quick-RNA Miniprep kit (ZYMO Research, CA, USA). cDNAs 
were then synthesized by RT-PCR with a SuperScript III First-Strand Synthesis 
System (Invitrogen, CA, USA). The synthesized cDNAs served as the template for 
qRT-PCR. Reactions were run using the iTaq Universal SYBR Green Supermix 
(Bio-Rad, CA, USA) in 20-µl reaction mixtures on a Bio-Rad iQ5 Real Time PCR 
Detection System (Bio-Rad, CA, USA). A pair of primers including PAL-RT-F and 
PAL-RT-R (Table 3) was used. 16S rDNA was chosen as the internal control with 
16S-RT-F and 16S-RT-R as the primers (Table 3). Initial denaturation was done at 
95 °C for 30 s, followed by 40 cycles of 95 °C for 15 s and 60 °C for 30 s. Data were 
analyzed with auto Ct (threshold cycle) and auto baseline functions of the system and 
Ct values of the triplicate reactions were averaged. ΔCt were determined as Ct 





4.2.8 Purification and structural analysis of the new fluorinated dicinnamoylmethane 
derivative 2 
The fermentation procedure was same as described above excepted that 3 mM 
2-fluoro-L-Phe was added instead of L-Phe after induction by 1 mM IPTG for 5 h at 
25 °C. The culture was incubated at 25 °C for an additional 60 h. The extract was 
analyzed by LC-MS. For large-scale preparation of the new fluorinated 
dicinnamoylmethane derivative 2, the fermentation was performed in 2 L of LB 
medium. The extract was first separated on a silica gel 60 open column, successively 
eluted with increasing concentrations of hexane/acetone (1:0, 9:1, 3:1, 1:1, and 0:1, 
v/v). The fractions containing 2 were lumped and further separated on a SUPELOD 
Supelcosil LC-PAH column (5 µm, 250 mm × 10 mm), eluted with acetonitrile-water 
(70:30, v/v) at a flow rate of 3 ml/min for 45 min purification. The peak at 35 min was 
collected and subjected to NMR analysis.   
4.3 Results 
4.3.1 Design of a reporter assay for PAL expression in E. coli  
Dicinnamoylmethane (1) is a curcuminoid synthesized by the sequential actions 
of PAL, 4CL and CUS (Fig. 15a). PAL catalyzes nonoxidative deamination of L-Phe 
to yield trans-cinnamic acid, which is then ligated with CoA by 4CL to generate 
cinnamoyl-CoA. CUS is a type III PKS and it takes two units of cinnamoyl-CoA and 




vivo activity of PALs by taking advantage of its yellow color. To this end, we 
designed a reporter assay system consisting of two plasmids that harbor 4CL and CUS, 
respectively (Fig. 15b). Specifically, a 4CL from A. thaliana, named 4CL1, was 
cloned into pET28a to yield pSW24, while CUS from O. sativa was inserted into 
pACYCDuet-1 to afford pSW54. A candidate PAL gene can be ligated into pSW54 
between PstI and NotI (or other available sites such as BamHI and EcoRI). All these 
three biosynthetic genes in pET28a and pACYCDuet-1 are under the control of 
separate T7 promoters. Co-expression of the resulting plasmids will build the 
necessary enzymatic platform for dicinnamoylmethane biosynthesis. The production 
of 1 will be visible because of its yellow color and the titer can be monitored by 
HPLC or UV-Vis microplate reader.   
 
Fig. 15 Design of a reporter assay for PALs. a. Biosynthetic pathway of 1 from L-Phe 
by the sequential actions of PAL, 4CL and CUS. b. A reporter assay for screening of 




the second one has 4CL1. A candidate PAL gene will be ligated into the second vector 
between PstI and NotI. Co-expression of the two plasmids will lead to the biosynthesis 
of 1, which is visible for its yellow color and can be analyzed by HPLC or UV-Vis 
microplate reader.  
4.3.2 Examination of the expression of three PALs from red clover in E. coli using the 
designed in vivo reporter assay 
To test the effectiveness of the designed in vivo reporter assay, we chose three 
plant PALs from T. pretense. The cDNAs encoding PAL1, PAL3 and PAL4 were 
individually introduced to pSW54 between the PstI and NotI sites to yield pSW56, 
pSW57 and pSW58 (Table 4), respectively. Color changes in the fermentation broths 
of E. coli/pSW24+pSW56, E. coli/pSW24+pSW57 and E. coli/pSW24+pSW58 were 
observed, compared to E. coli/pSW24+pSW54 that served as the negative control. 
LC-MS analysis of the extracts of these cultures revealed that E. coli/pSW24+pSW56, 
E. coli/pSW24+pSW57 and E. coli/pSW24+pSW58 produced the same yellow 
product 1 at 17.5 min, as shown in Fig. 16a. The ion peaks [M+H]
+
 at m/z 277.0 and 
[M+Na]
+
 at m/z 298.9 in the ESI-MS spectra suggested that 1 has a molecular weight 
of 276. This peak showed a maximum UV absorption at 390 nm, which is consistent 
with that for dicinnamoylmethane [26]. NMR analysis confirmed that the purified 
compound is dicinnamoylmethane [26]. These results suggested that all three tested 
PALs were functionally expressed in E. coli BL21 (DE3). We also found that more 





Fig. 16 HPLC-MS analysis of the production of 1 in engineered E. coli.a. HPLC 
traces of the methanol extract of the cell pellets of E. coli/pSW24+pSW54 (i), E. 
coli/pSW24+pSW56 (ii), E. coli/pSW24+pSW57 (iii) and E. coli/pSW24+pSW58 (iv); 
b. ESI-MS (+) spectrum of the peak at 17.5 min; c. UV absorption spectrum of the peak 
at 17.5 min. 
4.3.3 Development of a quantitative microplate-based assay for the production of 1  
To differentiate the titers of 1 by different PALs, a microplate-based assay was 
developed. Briefly, 1 ml of the fermentation broth was pelleted by centrifugation. The 




500 µl of methanol. The extracts were combined and dried under reduced pressure. 
The sample was then re-dissolved in methanol, distributed into a 96-well UV-plate 
and measured on a UV-Vis microplate reader at 390 nm. The concentrations were 
determined based on the standard curve of 1 (Fig. 17a). Using this assay, we 
conducted a time course analysis for E. coli/pSW24+pSW56, E. coli/pSW24+pSW57 
and E. coli/pSW24+pSW58. After the addition of L-Phe, glucose and CaCO3, the 
fermentation broths were sampled at 12, 24, 36, 48 60 and 72 h, and the titers of 1 are 
shown in Fig. 17b. It is apparent that E. coli/pSW24+pSW56 produced much higher 
amounts of 1 than E. coli/pSW24+pSW57 and E. coli/pSW24+pSW58 did, suggesting 
that the overall performance (expression and efficiency) of PAL1 is better than the 
other two PALs. The best titer of 1 by E. coli/pSW24+pSW56 that contains PAL1, 
4CL1 and CUS reached 0.36 g/l after 72 h, while the titers by PAL3 and PAL4 were 
only 0.08 g/l and 0.11 g/l, respectively. To validate the microplate-based assay, the 
same samples were analyzed by HPLC (Fig. 17c) and the titers of 1 were determined 
based on the areas of peak 1. Although there were occasional small differences 
between the HPLC and microplate reader measurements, which was likely due to the 
interfering compounds in the fermentation broth at different stages, overall the data 
from the microplate-based assay and HPLC analysis were consistent, indicating that 





Fig. 17 Time course analysis of the production of dicinnamoylmethane by the 
co-expression of 4CL1 and CUS with PAL1, PAL3 or PAL4. a. Standard curve of 
dicinnamoylmethane on a UV-Vis microplate reader at 390 nm; b. Time course 
analysis by a UV-Vis microplate reader at 390 nm; c. Validation of the 
microplate-based assay by HPLC analysis at 390 nm. 
4.3.4 qRT-PCR analysis of the expression of PAL1, PAL3 and PAL4 in E. coli 
We also used qRT-PCR to compare the expression level of the three plant PALs 
in E. coli/pSW24+pSW56, E. coli/pSW24+pSW57 and E. coli/pSW24+pSW58, 
respectively. As shown in Table 5, the qRT-PCR results indicated that the expression 
level of PAL1 was higher than the other two, and the expression level of the PAL3 
was the lowest among these three PALs. This is consistent with the analysis results of 
the titers of 1 in the corresponding E. coli strains, although the latter is the combined 



















































Table 5. Relative expression level of three different plant PALs in E. coli 
 
 
4.3.5 Precursor-directed biosynthesis of a new fluorinated dicinnamoylmethane 
derivative 
With the designed reporter assay, we determined that PAL1 showed the best 
performance in E. coli among the three tested plant PALs. We then used the strain E. 
coli/pSW24+pSW56 that expressed PAL1, 4CL1 and CUS for the synthesis of new 
curcuminoids. Previous studies have shown that it is possible to synthesize new 
curcuminoids with the curcuminoids biosynthetic enzymes by feeding different 
precursors [27, 28]. To this end, we fed 2-fluoro-L-Phe into the induced culture of E. 
coli/pSW24+pSW56 instead of L-Phe. As shown in Fig. 18a, LC-MS analysis 
revealed that three major curcuminoids were produced. In addition to 1, two new 
products 2 and 3 were synthesized. The ESI-MS spectra of 2 (Fig. 18b) revealed that 
it has a molecular weight of 294, suggesting that it is a monofluorinated derivative of 
1. The ESI-MS spectra of 3 (Fig. 18c) showed that this compound has a molecular 
weight of 312, suggesting that it has one more fluorine atom than 2 and is a 
difluorinated derivative of 1. While 6, 6'-difluoro-dicinnamoylmethane has been 
previously reported [27], 
13
C NMR spectrum of 2 revealed that it has a quaternary 
carbon at C-6 instead of a CH in 1. The chemical shift of C-6 is 163.3, suggesting 








6-fluoro-dicinnamoylmethane, which is a new compound. The proton and carbon 
signals are given in Appendix D. These two fluorinated products resulted from the 
incorporation of one and two 2-fluoro-L-Phe units, respectively.  
 
Fig. 18 LC-MS analysis of the production of a new fluorinated dicinnamoylmethane 
derivative 2 in E. coli.a. HPLC trace of the methanol extract of the cells of E. 
coli/pSW24+pSW56 supplemented with 2-fluoro-L-Phe; b. ESI-MS (+) spectrum of 2; 
c. ESI-MS (+) spectrum of 3. 
4.4 Conclusion 
PAL is a key enzyme involved in both primary and secondary metabolism, and 
has attracted more and more attention because of their applications in agriculture, 




the enzyme-based treatment or an industrial production process. Screening of efficient 
PALs is thus of significant interest. In this work, we developed a microplate-based 
reporter assay for screening of efficient PALs using the E. coli system, which is easily 
accessible. PAL is involved in the biosynthesis of many plant phenylpropanoids, 
among which curcuminoids are a group of yellow compounds synthesized from L-Phe 
by a type III polyketide biosynthetic pathway consisting of three enzymes. In this 
work, we developed a novel reporter assay for PALs using a two-plasmid screening 
system that expresses 4CL1 from A. thaliana and CUS from O. sativa. Together with 
any functional PAL, this system will yield 1, which allows efficient and visible 
screening of PALs in E. coli. Further development of the microplate-based assay, 
which was validated by HPLC analysis, will facilitate high throughput screening for 
efficient PALs.  
 
Biological reporter systems have been developed for different uses in research 
and industry. For example, a reporter assay has recently been developed for bacterial 
and mammalian cells based on the blue color of the non-ribosomal peptide 
indigoidine. Indigoidine is synthesized from two units of L-glutamine [29]. 
Accordingly, the designed system consisted of the Streptomyces lavendulae 
non-ribosomal peptide synthetase BpsA and the Streptomyces verticillus 
4'-phosphopantetheinyl transferase Svp that activates the thiolation domain in BpsA 




similar screening system in other hosts such as yeasts and mammalian cells for 
different purposes with the help of synthetic biology techniques.  
 
The tested three PALs were from red clover (T. pratense). PAL3 and PAL4 are 
nearly identical with 97% identity, and they share only 89% identity with PAL1. 
These enzymes are involved in the biosynthesis of phenylpropanoid compounds in the 
plant, and PAL3 and PAL4 were also reported to participate in pathogen defense 
response [31]. However, no biochemical studies on these enzymes have been 
performed and their catalytic activities remain unknown. We compared these three 
PALs in E. coli using the designed reporter assay and found that PAL1 showed the 
best overall performance, which is a combined effect of the expression level and 
catalytic efficiency. Furthermore, the qRT-PCR analysis confirmed that the 
expression level of PAL1 was the highest in E. coli among the three tested PALs. It is 
known that many molecular technology tools, such as RT-PCR, SDS-PAGE and 
western blotting, can be used to analyze protein expression at the transcriptional or 
translational level. However, these analyses are often time-consuming and more 
costly. The reporter assay we established provides a novel, visible and easy-to-assay 
approach for screening highly efficient PALs, which requires remarkably smaller 
volumes, lower costs and shorter time compared to traditional analytic methods. 
Furthermore, the results from this assay directly reveal the overall performance of 





With the successful screening of the most efficient enzyme from a group of plant 
PALs, this reporter assay can be further utilized to screen more efficient PALs from a 
larger library for the production of useful products. In this work, the titer of 1 reached 
0.36 g/l in E. coli. Because more than 71% of the product is in the cells, the screening 
can be further simplified by focusing on the cells and discarding the supernatants after 
centrifugation. Precursor-directed biosynthesis of 2 and 3 revealed that PAL1 can 
deaminate 2-fluoro-L-Phe to yield the corresponding fluorinated trans-cinnamic acid, 
which is then processed by 4CL1 and CUS to generate the fluorinated curcuminoids. 
This confirmed that the three biosynthetic enzymes including PAL1, 4CL1 and CUS 
have relatively flexible substrate specificity, thus opening an opportunity to 
synthesize novel curcuminoids by feeding different precursors.     
4.5 Acknowledgments 
We thank Dr. Mike Sullivan (USDA), Dr. Claudia Schmidt-Dannert (University 
of Minnesota) and Dr. Nobutaka Funa (University of Shizuoka) for providing the 
corresponding plasmids. This research was supported by Award 
W81XWH-11-1-0458 from the Congressionally Directed Medical Research Programs 





1. Dixon RA, Paiva NL (1995) Stress-induced phenylpropanoid metabolism. Plant 
Cell 7:1085-1097  
2. Hahlbrock K SD (1989) Physiology and molecular biology of phenylpropanoid 
metabolism. Annu Rev Plant Physiol Plant Mol Biol 40:347–369 
3. MacDonald MJ, D'Cunha GB (2007) A modern view of phenylalanine ammonia 
lyase. Biochem Cell Biol 85:273282 
4. Koukol J, Conn EE (1961) Metabolism of aromatic compounds in higher plants. 
IV. Purification and properties of the phenylalanine deaminase of Hordeum 
vulgare. J Biol Chem 236:29622968 
5. Calabrese JC, Jordan DB, Boodhoo A, Sariaslani S, Vannelli T (2004) Crystal 
structure of phenylalanine ammonia lyase: Multiple helix dipoles implicated in 
catalysis. Biochemistry 43:114031141 
6. Ritter H, Schulz GE (2004) Structural basis for the entrance into the 
phenylpropanoid metabolism catalyzed by phenylalanine ammonia-lyase. Plant 
Cell 16:34263436 
7. Gamez A, Wang L, Sarkissian CN, Wendt D, Fitzpatrick P, Lemontt JF, Scriver 
CR, Stevens RC (2007) Structure-based epitope and PEGylation sites mapping of 
phenylalanine ammonia-lyase for enzyme substitution treatment of 
phenylketonuria. Mol Genet Metab 91:325334  
8. Ikeda K, Schiltz E, Fujii T, Takahashi M, Mitsui K, Kodera Y, Matsushima A, 




with polyethylene glycol: Potential therapeutic agent for phenylketonuria. Amino 
Acids 29:283287  
9. Sarkissian CN, Gamez A (2005) Phenylalanine ammonia lyase, enzyme 
substitution therapy for phenylketonuria, where are we now? Mol Genet Metab 
86:S22S26  
10. Evans CT, Conrad D, Hanna K, Peterson W, Choma C, Misawa M (1987) Novel 
stabilization of phenylalanine ammonia-lyase catalyst during bioconversion of 
trans-cinnamic acid to L-phenylalanine. Appl Microbiol Biotechnol 25:399405  
11. D'Cunha GB, Satyanarayan V, Nair PM (1994) Novel direct synthesis of 
L-phenylalanine methyl ester by using Rhodotorula glutinis phenylalanine 
ammonia lyase in an organic-aqueous biphasic system. Enzyme Microb Technol 
16:318322 
12. Xiang L, Moore BS (2005) Biochemical characterization of a prokaryotic 
phenylalanine ammonia lyase. J Bacteriol 187:42864289 
13. Vogt T (2009) Phenylpropanoid biosynthesis. Mol Plant 3:220 
14. Dixon RA, Paiva NL (1995) Stress-induced phenylpropanoid metabolism. Plant 
Cell 7:1085-1097 
15. Aggarwal BB, Harikumar KB (2009) Potential therapeutic effects of curcumin, 
the anti-inflammatory agent, against neurodegenerative, cardiovascular, 





16. Aggarwal BB, Kumar A, Bharti AC (2003) Anticancer potential of curcumin: 
Preclinical and clinical studies. Anticancer Res 23:363398  
17. Aggarwal BB, Sundaram C, Malani N, Ichikawa H (2007) Curcumin: The Indian 
solid gold. Adv Exp Med Biol 595:175 
18. Debjit B, Chiranjib, Kumar KPS, Margret C, Jayakar B (2009) Turmeric: a herbal 
and traditional medicine. Arch Appl Sci Res 1:86108 
19. Goel A, Kunnumakkara AB, Aggarwal BB (2008) Curcumin as "Curecumin": 
From kitchen to clinic. Biochem Pharmacol 75:787809 
20. Hamaguchi T, Ono K, Yamada M (2010) Review: Curcumin and Alzheimer's 
disease. CNS Neurosci Ther 16:285297 
21. Hatcher H, Planalp R, Cho J, Tortia FM, Torti SV (2008) Curcumin: From ancient 
medicine to current clinical trials. Cell Mol Life Sci 65:16311652 
22. Kurup VP, Barrios CS (2008) Immunomodulatory effects of curcumin in allergy. 
Mol Nutr Food Res 52:10311039 
23. Lee SY, Yuk DY, Song HS, Yoon DY, Jung JK, Moon DC, Lee BS, Hong JT 
(2008) Growth inhibitory effects of obovatol through induction of apoptotic cell 
death in prostate and colon cancer by blocking of NF-kappa B. Eur J Pharmacol 
582:1725 
24. Moon DO, Kim MO, Lee HJ, Choi YH, Park YM, Heo MS, Kim GY (2008) 
Curcumin attenuates ovalbumin-induced airway inflammation by regulating nitric 




25. Katsuyama Y, Kita T, Funa N, Horinouchi S (2009) Curcuminoid biosynthesis by 
two type III polyketide synthases in the herb Curcuma longa. J Biol Chem 
284:1116011170 
26. Katsuyama Y, Matsuzawa M, Funa N, Horinouchi S (2008) Production of 
curcuminoids by Escherichia coli carrying an artificial biosynthesis pathway. 
Microbiology 154:26202628 
27. Katsuyama Y, Hirose Y, Funa N, Ohnishi Y, Horinouchi S (2010) 
Precursor-directed biosynthesis of curcumin analogs in Escherichia coli. Biosci 
Biotechnol Biochem 74:641645 
28. Yu D, Xu F, Zeng J, Zhan J (2012) Type III polyketide synthases in natural 
product biosynthesis. IUBMB Life 64:285295 
29. Yu D, Xu F, Valiente J, Wang S, Zhan J (2013) An indigoidine biosynthetic gene 
cluster from Streptomyces chromofuscus ATCC 49982 contains an unusual IndB 
homologue. J Ind Microbiol Biot 40:159168 
30. Muller M, Auslander S, Auslander D, Kemmer C, Fussenegger M (2012) A novel 
reporter system for bacterial and mammalian cells based on the non-ribosomal 
peptide indigoidine. Metab Eng 14:325335 
31. Sullivan ML (2009) Phenylalanine ammonia lyase genes in red clover: Expression 





CHAPTER 5 BIOSYNTHESIS AND ANTIBACTERIAL ACTIVITY OF 
DUTOMYCIN AND ANALOGS  
ABSTRACT 
Dutomycin, an anthracycline natural product, was isolated with its precursor 
POK-MD1 from Streptomyces minoensis NRRL B-5482. A putative dutomycin 
biosynthetic gene cluster was discovered by genome sequencing and its involvement 
in dutomycin biosynthesis was confirmed by disruption of the ketosynthase gene. The 
open reading frames were analyzed and annotated based on the sequence homology. 
Two polyketide synthases (PKSs) are present in the gene cluster, including a type II 
PKS and an iterative type I PKS. The minimal type II PKS (DutA, DutB and DutC) 
synthesizes the nascent poly-β-ketone chain, which is subjected to extensive 
modifications by tailoring enzymes such as oxygenases, methyltransferases and 
glycosyltransferases to afford POK-MD1. The type I PKS DuG repeatedly uses its 
active sites to create a 9-carbon triketide chain that is subsequently transferred to the 
second sugar moiety at 4"-OH of POK-MD1 to yield dutomycin. Using a 
heterologous recombination approach, we disrupted four genes including two 
methyltransferases (dutMT1 and dutMT2) and two glycosyltransferases (dutGT1 and 
dutGT2). Analysis of the metabolites of these mutants revealed the functions of these 
genes and yielded three new dutomycin analogs SW140, SW82 and SW75. 
Dutomycin, POK-MD1, SW82 and SW75 were subjected to the antibacterial assay. 




activity against Gram-positive bacteria Staphylococcus aureus (SA) and 
methicillin-resistant S. aureus (MRSA). In contrast, POK-MD1 and SW75 have no 
activities at test concentrations up to 250 g/ml, indicating the essential role of the 
9-carbon polyketide chain attached to 4"-OH. While the MICs of dutomycin against 
SA and MRSA were determined to be 0.25 µg/ml, it is interesting that SW82 has 
stronger activity with the MICs 0.125 µg/ml against the same strains, indicating that 
the antibacterial activity of these molecules can be improved by biosynthetic 
structural modifications.   
5.1 Introduction  
Antibiotics play a critical role in treating bacterial infections and have saved 
millions of lives. The first antibiotic was discovered in 1928, and since then, more 
natural compounds with promising antibacterial activities have been identified and 
used as anti-infectious drugs such as tetracycline and kanamycin. However, extensive 
uses of antibiotics also led to the emergence of drug resistance. For example, 
methicillin-resistant Staphylococcus aureus (MRSA) is considered a "superbug" 
because its ability to fight off treatment, including the antibiotic methicillin. Spread of 
these antibiotic-resistant bacterial pathogens poses a serious threat to public health. 
Therefore, there is an urgent need for new generation antibiotics that can directly 





Natural products are an important source of new drugs. In fact, many clinically 
used antibiotics are natural products including tetracycline, penicillin, and 
vancomycin. Actinomycetes are a major group of producers of many antibiotics. 
Continuous search for new antimicrobial molecules from nature is critical for 
development of new antibiotics. On the other hand, engineered biosynthesis can 
complement the time-consuming and resource-intensive discovery process, and 
represents an attractive approach to creating molecular diversity for drug discovery. 
Novel “unnatural” natural products can be obtained through direct genetic 
modification of the biosynthetic pathway in the producing strains or combinatorial 
biosynthesis in a heterologous host. Polyketides are a large group of medicinally 
important natural products, exemplified by lovastatin (anti-cholesterol), 
oxytetracycline (antibacterial), pradimicin A (antifungal and antiviral), and 
erythromycin (antibacterial). These molecules are assembled by polyketide synthases 
(PKSs) and associated tailoring enzymes through stepwise condensations of simple 
carboxylic acid precursors and further structural decorations [1]. PKSs are classified 
into three types. Type I PKSs such as DEBS involved in erythromycin biosynthesis 
are modular enzymes that contain a series of catalytic domains [2]. Ketosynthase (KS), 
acyl transferase (AT) and acyl carrier protein (ACP) are essential domains for 
polyketide chain elongation. Reductive domains such as ketoreductase (KR), 
dehydratase (DH) and enoyl reductase (ER) are also often found in type I PKSs. Type 




the polyketide structures. KS, chain length factor and ACP are the minimal PKS to 
form the nascent poly-β-ketone chain, which is subjected to the modifications by 
tailoring enzymes such as KR, aromatase (ARO), cyclase (CYC), oxygenase, 
methyltransferase (MT) and glycosyltransferase (GT) to form diverse aromatic 
molecules [3]. Type III PKSs are single enzymes that form a dimeric structure to 
catalyze substrate loading, chain elongation, and cyclization [4]. PKSs are one of the 
most amenable systems for engineered biosynthesis because of their inherent genetic 
organization and ability to produce structurally and functionally diverse molecules 
[5].  
 
Here, we report the isolation and identification of the anthracycline antibiotic 
dutomycin (4, Fig.19) and its precursor POK-MD1 (5, Fig.19) from Streptomyces 
minoensis NRRL B-5482. The dutomycin biosynthetic gene cluster was then 
discovered by genome sequencing and confirmed by disrupting the ketosynthase gene. 
Functions of several tailoring enzymes were identified by targeted gene disruption 
and three new dutomycin analogs (6-8, Fig.19) were generated. Compounds 4-7 were 
tested for their antibacterial activity and 6 was found to have better activity against 
SA and MRSA than the natural product 4. This work not only provides useful 
information about the formation of dutomycin and the structure-activity relationship 
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Fig. 19 Structures of dutomycin (4) and analogs 5-8. 
5.2 Materials and methods 
5.2.1 General Equipment.  
Products were analyzed and purified on an Agilent 1200 HPLC instrument with 
an Agilent Eclipse XDB-C18 column (5 μm, 250 × 4.6 mm). The samples were eluted 
with acetonitrile-water (30:70, v/v to 95:5, v/v) at a flow rate of 1 ml/min for 30 min 
and detected at 460 nm. ESI-MS spectra were obtained on an Agilent 6130 
quadrupole LC-MS in the negative mode. 1D and 2D NMR spectra were recorded on 
a JEOL ECX-300 NMR instrument (300 MHz for 
1
H NMR and 75 MHz for 
13
C 
NMR). The chemical shift (δ) values are given in parts per million (ppm). The 
coupling constants (J values) are reported in hertz (Hz). 




S. minoensis NRRL B-5482 was obtained from the USDA Agricultural Research 
Service Culture Collection. E. coli ATCC 25922, S. aureus ATCC 25923 and 
methicillin-resistant S. aureus ATCC 33591 were purchased from the American Type 
Culture Center and used for the antibacterial assay.  E. coli XL-1 Blue (Stratagene) 
and the pJET1.2 cloning vector (Fermentas) were used for routine subcloning. E. coli 
ET12567 (pUZ8002) and pKC1139 vector were used for the gene disruption 
experiments [20].  
5.2.3 Media and Culture Conditions.  
S. minoensis NRRL B-5482 and its mutants were maintained on YM (yeast 
extract-malt extract) agar plate at 28
o
C [21]. S. aureus and E. coli were cultured in 
Luria-Bertani (LB) broth at 37
o
C. MS [21], ISP4, and TSB media were used in the 
conjugation. Ampicillin (50µg/ml) and apramycin (50µg/ml) were added to the media 
appropriately for the cloning and conjugation. 
5.2.4 Extraction and Sequencing of the Genomic DNA.  
S. minoensis NRRL B-5482 was grow in 50 ml of YM medium at 28
o
C with 
shaking at 250 rpm for 5 days. The genomic DNA was extracted as previously 
reported. The genome was then sequenced using an Illumina MiSeq desktop 
sequencer and assembled with the short read de novo assembler Velvet. The genome 




The dutomycin gene cluster was deposited in GenBank under accession number 
KP710956. 
5.2.5 Construction of Plasmids.  
To disrupt three different ks fragments, dutMT1, dutMT2, dutGT2 and dutGT1 in 
S. minoensis, a homologous recombination single crossover approach was used. To 
find the type II KS involved in dutomycin biosynthesis, a ~0.6-kb fragment was 
amplified from the genomic DNA of S. minoensis using a pair of degenerated primers 
(KSα-F  and KSα-R, Table S1) with a 30-cycle PCR program (15 s at 98
o
C, 15 s at 
55
o
C, and 30 s at 72
o
C). The PCR product was ligated into pJET1.2 vector to yield 
pLS51, pLS52 and pLS53 based on the sequencing results. The three different ks 
fragments in these plasmids were then excised and ligated into pKC1139 between 
BglII and BamHI to afforded pLS54, pLS55 and pLS56, respectively.  For 
inactivation of dutMT1, dutMT2, dutGT2 and dutGT1, 0.6-kb fragments of these 
genes were amplified from the genomic DNA with primer paris 
DutMT1-F/DutMT1-R, DutMT2-F/DutMT2-R, DutGT2-F/DutGT2-R, and 





C, and 30 s at 72
o
C) and ligated to pJET1.2 to yield pSW70, pSW82, pSW83 
and pSW138, respectively. After the sequences were confirmation by sequencing, 
these gene fragments were introduced to pKC1139 to form pSW75, pSW85, pSW91 
and pSW140 between HindIII and XbaI. All the plasmids used in this study are listed 




Table 6. Plasmids used in Chapter 5. 
Plasmid Description Reference 
pLS51 ks1 in pJET1.2 this work 
pLS52 ks2 in pJET1.2 this work 
pLS53 ks3 in pJET1.2 this work 
pLS54 ks1 in pKC1139 this work 
pLS55 ks2 in pKC1139 this work 
pLS56 ks3 in pKC1139 this work 
pSW70 dutGT2 fragment in pJET1.2 this work 
pSW75 dutGT2 fragment in pKC1139 this work 
pSW82 dutMT1 fragment in pJET1.2 this work 
pSW83 dutMT2 fragment in pJET1.2 this work 
pSW85 dutMT2 fragment in pKC1139 this work 
pSW91 dutMT1 fragment in pKC1139 this work 
pSW138 DutGT1 fragment in pJET1.2 this work 
pSW140 DutGT1 fragment in pKC1139 this work 
5.2.6 Conjugation and Confirmation of the Mutants.  
The gene disruption plasmids were introduced to E. coli ET12567 (pUZ8002) 
through chemical transformation. Plasmids were introduced into S. minoensis NRRL 
B-5482 by E. coli–Streptomyces conjugation, following the procedure as reported [22, 
23]. The resulting E. coli strains were used as donors and S. minoensis NRRL B-5482 
was the acceptor. The positive colonies were picked to TSB medium with 50 µg/ml of 
apramycin after 20 days of culture on MS plates. The colonies were grown in TSB 
medium at 28
o 
C for 5 days and 50 µl of these cultures were spread on ISP4 plates 
with 50 µg/ml of apramycin. Colonies showing up at 37
o
C were considered as 
asrecombination strains, which were further cultured on YM plate with the 50 µg/ml 
of apramycin at 28
o
C for product checking. The mutants were confirmed by PCR 




PCR program (30 s at 98
o
C, 30 s at 58
o
C, and 60 s at 72
o
C). The PCR verification 
results are shown in Appendix E.  
5.2.7 Extraction, Analysis and Purification of Compounds.  
S. minoensis NRRL B-5482 and its knockout mutants were grown on YM agar 
plates (with or without apramycin). The cultures were extracted three times with an 
equal volume of ethyl acetate. The extracts were then dried under reduced pressure 
and re-dissolved in methanol for LC-MS analysis. To isolate compounds 4 and 5,  1 l 
of culture of wild type S. minoensis NRRL B-5482 was extracted and subjected to 
silica gel 60 column chromatography, eluted with 100:0, 75:25, 50:50, 25:75, 0:100 % 
CHCl3-MeOH (v/v) to yield 5 fractions. The fraction (75:25) was found to contain 4.  
It was further separated by HPLC with an Agilent Eclipse XDB-C18 column (5 μm, 
250 × 4.6 mm) and eluted with a gradient of acetonitrile-water (70:30, v/v to 75:25, 
v/v in 20 min) at 1 ml/min. The peak at 17 min was collected to yield 48.7 mg of 4 in 
pure form. Similarly, the fraction (50:50) containing 5 was separated by the same 
HPLC instrument, eluted with acetonitrile-water from 30:70, v/v to 35:65, v/v in 15 
min at 1 ml/min, to yield 6.2 mg of 5. A total of 38.9 mg of 6 was isolated from 1 l of 
S. minoensis-ΔMT1 culture using the same procedure as for 4. For the purification of 
7, the extract of 1 l of S. minoensis-ΔGT2 culture was separated on a MCI column, 
eluted with 0:100, 25:75, 50:50, 75:25, 100:0% MeOH-H2O (v/v) to yield 5 fractions. 
The 100% MeOH fraction was found to contain 7 which was further separated by 




was eluted with acetonitrile-water 30:70 (v/v) at 1 ml/min for 15 min, and the peak at 
12 min was collected to yield 15.4 mg of 7 in pure form. All these compounds were 
subjected to NMR and MS analyses. The major product 8 in S. minoensis-ΔDutGT1 
was identified by MS and a comparison with the methanolysis product of 4. 
5.2.8 Minimum inhibition concentration test.  
E. coli XL-1 Blue, S. aureus ATCC 25923 and methicillin-resistant S. aureus 
ATCC 33591 were incubated in LB broth with the test samples at different 
concentrations (64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125, and 0.064 µg/ml) at 37°C in 
96-well plates, and the growth was analyzed after 20 hours to determine the MICs. 
5.3 Results  
5.3.1 Isolation and Identification of Two Anthracyclines from S. minoensis NRRL 
B-5482.  
HPLC analysis of the ethyl acetate extract of the culture of S. minoensis NRRL 
B-5482 on YM agar at 460 nm showed a major product at 25.6 min (4) and a minor 
metabolite at 10.4 min (5), respectively (trace i, Fig. 20). Both compounds shared the 
typical UV absorptions of anthracycline antibiotics (Appendix E), suggesting that 
they might be structurally related analogs. ESI-MS spectrum of 4 showed the [M-H]
-
 
ion peak at m/z 854.2 (Appendix E), suggesting that it has a molecular weight of 854, 
which is the same as dutomycin, an anticancer agent previously isolated from 








data, which confirmed that 4 is dutomycin (Fig. 19).  ESI-MS analysis revealed that 
the molecular weight of 5 is 716 based on the [M-H]
-
 peak at m/z 715.1 (Fig. S2), 
suggesting that 5 is a dutomycin derivative that lacks the C-4" side chain. This 
compound was previously found in the ΔpokMT1 mutant of the 
polyketomycin-producing strain Streptomyces diastatochromogenes Tü6028, and was 
named POK-MD1. However, this compound was not structurally characterized. Thus, 
5 was subjected to a complete NMR analysis. The 
13
C NMR spectrum of 5 showed 35 
carbon signals, which are 9 carbons than 4. A comparison of the spectra with those of 
4 revealed that the carbon signals of the 9-carbon side chain at C-4" were missing. 





NMR signals were assigned and are shown in Tables 7 and 8, respectively.  
 
Fig. 20 HPLC analysis of the metabolites of wide type (WT) S. minoensis 













C NMR data (75 MHz) for 4-7 (4 and 6 in CDCl3, 5 in CD3OD, and 7 in 
DMSO-d6). 
Position 4 5 6 7 
1a 132.9 133.9 133.9 132.0 
1 181.5 182.8 179.1 181.0 
2 161.3 162.7 160.7 161.7 
3 108.8 109.6 110.6 108.4 
4 190.4 189.5 189.8 190.7 
4a 113.8 114.9 113.6 111.3 
5 162.5 163.3 163.7 160.6 
5a 123.5 124.5 123.3 123.2 
6 192.6 192.2 190.5 193.5 
6a 81.2 83.4 81.5 82.2 
7 195.2 195.3 195.4 196.5 
8 110.8 112.6 110.7 112.8 
9 191.2 192.2 191.7 191.5 
10 73.9 73.2 73.5 74.4 
11a 75.7 75.6 75.7 75.8 
11 35.0 35.5 36.8 34.1 
12a 150.9 152.8 150.1 151.0 
12 132.4 133.8 120.1 131.5 
13 16.8 17.0 - 16.1 
14 200.9 200.5 201.3 198.5 
15 26.7 27.7 25.9 26.3 
16 57.1 57.7 57.1 57.1 
1' 102.2 103.5 102.2 101.5 
2' 29.5 30.6 29.5 30.2 
3' 30.3 31.3 30.3 30.7 
4' 80.1 81.3 80.1 70.2 
5' 74.5   74.7 74.6 75.2 
6' 17.4 17.9 18.1 16.9 
1'' 100.3 101.3 100.4  
2'' 37.0 37.1 37.1  
3'' 68.9 70.6 69.0  
4'' 74.2 75.2 74.2  
5'' 62.8 64.5 62.9  
6'' 16.8 17.2 16.8  
7'' 25.9 27.0 25.9  
1''' 167.4  167.5  
2''' 125.2  125.3  
3''' 21.1  21.1  
4''' 150.1  150.1  
5''' 33.5  33.5  
6''' 20.7  20.8  
7''' 39.8  39.8  




9''' 14.4  14.4  
Table 8. 
1
H NMR data (300 MHz) for 4-7 (4 and 6 in CDCl3, 5 in CD3OD, and 7 in 
DMSO-d6). 
Position 4 5 6 7 
3 6.11 (1H, s) 6.26 (1H, s) 6.17 (1H, s) 6.36 (1H, s) 
5-OH 14.17 (1H, s) - 13.50(1H, s) 14.10 (1H, s) 
10 4.43 (1H, brs) 4.46 (1H, brs) 4.46 (1H, brs) 4.24 (1H, brs)
 
11 3.78 (1H, d, 17.5) 
3.01 (1H, m) 
3.78 (1H, d, 17.5) 
3.03 (1H, m) 
3.75 (1H, d, 17.5) 
3.05 (1H, m) 
3.58 (1H, d, 17.5) 
2.95 (1H, d, 17.8) 
12 - - 7.53 (1H, s) - 
13 2.57 (3H, s) 2.60 (3H, s) - 2.48 (3H, s) 
15 2.70 (3H, s) 2.65 (3H, s) 2.70 (3H, s) 2.58 (3H, s) 
16 3.93 (3H, s) 3.93 (3H, s) 3.95 (3H, s) 3.90 (3H, s) 
1' 4.66 (1H, d, 8.2) 4.67 (1H, brs) 4.71 (1H, d, 8.2) 4.52 (1H, d, 8.2) 
2' 1.57 (1H, m) 
2.18 (1H, m) 
1.57 (1H, m) 
2.12 (1H, m) 
1.56 (1H, m) 
2.18 (1H, m) 
1.45 (1H, m) 
1.90 (1H, m) 
3' 2.11 (1H, m) 
1.63 (1H, m) 
2.12 (1H, m) 
1.61 (1H, m) 
2.12 (1H, m) 
1.66 (1H, m) 
1.90 (1H, m) 
1.25 (1H, m) 
4' 3.11 (1H, m) 3.10 (1H, m) 3.13 (1H, m) 2.83 (1H, brs) 
5' 3.02 (1H, m) 2.95 (1H, m) 3.04 (1H, m) 2.83 (1H, brs) 
6' 0.58 (3H, d, 5.5) 0.56 (3H, m) 0.68 (3H, d, 5.5) 0.42 (3H, d, 4.5) 
1'' 4.97 (1H, d, 3.1) 4.95 (overlapped) 4.99 (1H, d, 2.3)  
2'' 1.88 (1H, m) 
1.60 (1H, m) 
1.85 (1H, m) 
1.60 (1H, m) 
1.86 (1H, m) 
1.60 (1H, m) 
 
4'' 4.76 (1H, s) 4.86 (overlapped) 4.76 (1H, s)  
5'' 4.38 (1H, q, 6.5) 4.30 (1H, q, 6.3) 4.38 (1H, q, 6.5)  
6'' 1.07 (3H, d, 6.9) 1.19 (3H, d, 6.9) 1.07 (3H, d, 6.9)  
7'' 1.07 (3H, s) 1.14 (3H, s) 1.08 (3H, s)  
3''' 1.91 (3h, s)  1.92 (3H, s)  
4''' 5.70 (1H, dd, 1.0, 
11.3) 
 5.71 (1H, d, 10.3)  
5''' 3.07 (1H, m)  3.10 (1H, m)  
6''' 0.96 (3H, d, 6.5)  0.97 (3H, d, 6.6)  
7''' 1.25 (2H, m)  1.26 (2H, m)  
8''' 1.25 (2H, m)  1.26 (2H, m)  
9''' 0.86 (3H, t, 6.5)  0.87 (3H, t, 6.5)  
4 and 5 are two anthracyclines that feature a tetracyclic quinone core structure 
and two sugar moieties, β-D-amicetose and α-L-axenose. The structures of 4 and 5 
differ in the C-4" side chain. We proposed that 5 serves as a biosynthetic intermediate 
in dutomycin biosynthesis. A time course analysis of the production of 4 and 5 was 




and then decreased with longer culture time, while the production of 4 kept increasing 
over the time. After 10 days, the production of 5 cannot be detected. This observation 
supports that 5 is a precursor of 4. The titer of 4 reached 82.5±1.8 mg/l at 10 days.  
5.3.2 Identification of a Ketosynthase Gene Involved in Dutomycin Biosynthesis.  
The structures of 4 and 5 indicated that they are synthesized through a type II 
polyketide biosynthetic pathway. We used a pair of degenerated primers, KSα-F 
(5'-TSGCSTGCTTCGAYGCSATC-3') and KSα-R (5'-TGGAANCCGCCGAABCC 
GCT-3') [6] to amplify the KS gene fragment from the genome of S. minoensis NRRL 
B-5482. These primers were used to amplify the conserved region of KS genes. A 
0.6-kb fragment was obtained and ligated to pJET1.2. Sequencing of ten correct 
clones revealed three different KS genes that are homologous to reported KS genes in 
GenBank. These genes were named ks1, ks2 and ks3, indicating that there are multiple 
type II polyketide biosynthetic gene clusters in this strain. To identify which ks gene 
is involved in dutomycin biosynthesis, we ligated these three fragments into 
temperature-sensitive E. coli-Streptomyces shuttle vector pKC1139 to yield the 
corresponding plasmids pLS54, pLS55 and pLS56 (Table 6). These plasmids were 
transferred into S. minoensis NRRL B-5482 through conjugation. Analysis of the 
products of the mutants revealed that the production of 4 and 5 was abolished in S. 
minoensis NRRL B-5482/pLS54 (trace ii, Fig.20), while the other two mutants still 
produced the two compounds (data not shown). Thus, ks1 was identified to be 




5.3.3 Genome Sequencing and Discovery of the Dutomycin Biosynthetic Gene 
Cluster. 
To locate the dutomycin (dut) biosynthetic gene cluster and better understand this 
strain, the genomic DNA of S. minoensis NRRL B-5482 was extracted and sequenced, 
yielding approximately 10.4 Mb of sequence data (GC content of 70.1%). We then 
searched the sequencing data using ks1 that was found to be involved in dutomycin 
biosynthesis. A gene cluster covering 47.5-kb regions, which has 39 open reading 
frames (ORFs) (Fig. 21A), were identified. It was deposited into GenBank under 
accession number KP710956. Based on sequence homology search through BLAST, 
the putative functions of these ORFs are given in Table 4. Many of the genes are 
homologous to the previously reported polyketomycin biosynthetic genes. Based on 
the putative functions of these genes, a dutomycin biosynthetic pathway is proposed 


















































































































Fig. 21 The biosynthetic gene cluster of dutomycin (dut) (A) and the proposed 
biosynthetic pathway (B). 
DutA, B and C are the KS, CLF, and ACP, respectively. They form the minimal 
PKS that generates the nascent poly-β-ketone chain from 10 units of malonyl-CoA. 
The ks1 fragment amplified for the gene disruption above is a part of dutA. Specific 
primers including DutA-Check1 and DutA-Check2 were then designed (Appendix E). 
Together with the vector-specific primers M13-47 and RM-V, the disruption of ks1 
gene in S. minoensis NRRL B-5482/pLS54 was confirmed by PCR (Appendix E), 
further supporting that ks1/dutA is involved in dutomycin biosynthesis.  
 
The dut biosynthetic gene cluster contains a variety of tailoring enzymes. The 
decaketide chain synthesized by the dut minimal PKS was then cyclized by the 
immediate tailoring enzymes including DutD (aromatase), DutE (cyclase) and DutF 




additional tailoring enzymes such as oxygenases (DutO1-O4) and methyltransferases 
(DutMT1 and DutMT2) to afford the aglycone 8. Nine deoxysugar biosynthetic genes 
were found in the dut gene cluster and named dutS1-S9. These genes are proposed to 
synthesize the two NDP-deoxysugars, including NDP-D-amicetose and 
NDP-L-axenose from glucose-1-phosphate [7]. Two GTs, DutGT1 and DutGT2, then 
transfer the sugar moieties to 10-OH of 8 to 5. DutG is an iterative highly reducing 
type I PKS. It consists of six domains, including KS, AT, DH, ER, KR and ACP. 
Analysis of the sequence of the AT domain showed the GHSXG motif. The previous 
research reported that “X” in malonyl-specific ATs is usually a branched hydrophobic 
amino acid such as valine (V) or isoleucine (I), while ATs that have a less bulky 
residue such as glutamine (Q) or methionine (M) at this position select other 
substrates including methylmalonate [2, 8, 9] . DutG-AT has a GHSMG motif, 
suggesting that it selects a substrate other than malonyl-CoA. Based on the structure 
of C-4" side chain of 4, it is apparent that the AT should takes malonyl-CoA as the 
substrate. This was confirmed by the presence of the motif of VASH. It has been 
previously reported that a conserved [YVW] ASH motif is present in 
methylmalonyl-specific ATs, while a [HTVY] AFH motif is found in 
malonyl-specific ATs [10] . DutG selectively and repeatedly uses its reduction 
domains to generate a triketide chain from three units of methylmalonyl-CoA. An 
ACP shuttle-type acyltransferase (DutH) then transfers the triketide chain to the 




found in the dut gene cluster, dutK and dutV. The gene cluster also contains two ABC 
transporter genes dutT and dutU, which are likely involved in transporting the final 
product out of the cells. 
5.3.4 Inactivation of Two Putative MTs (DutMT1 and DutMT2) Involved in 
Decorating the Aglycone and Isolation of a New Demethylated Derivative of 
Dutomycin.  
DutMT1 and DutMT2 are two MTs that are supposed to be involved in the 
synthesis of the aglycone 8. To understand their roles in dutomycin biosynthesis and 
create new analogs, we disrupted these two genes in S. minoensis NRRL B-5482 
using the same approach for ks1-ks3 described above. To this end, a fragment of 
dutMT1 or dutMT2 was amplified and ligated to pKC1139 to yield the corresponding 
disruption plasmid pSW91 and pSW85, respectively. Integration of pSW91 into the 
genome of S. minoensis NRRL B-5482 was screened by the apramycin resistance. An 
apramycin-resistant mutant was subjected to PCR analysis. As shown in Appendix E, 
~1.0 kb gene fragments were amplified from the mutant using primer pairs 
M13-47/DutMT1-Check1 (lane 3) and RM-V/DutMT1-Check2 (lane 4), while no 
products were obtained from the wild type using the same primers. This result 
confirmed that pSW91 successfully inserted into dutMT1 to yield the desired 
ΔDutMT1 mutant. The products of this mutant were analyzed by LC-MS. As shown 
in Fig. 22, the production of 4 in S. minoensis NRRL B-5482-ΔDutMT1 was not 




a scaled-up culture of this mutant for structural characterization. ESI-MS analysis 
revealed that the molecular weight of 6 is 840 according to the [M-H]
-
 ion peak at m/z 
839.1 (Fig. S2), which is 14 mass units smaller than 4. The 
13
C NMR spectrum of 6 
showed 43 carbons, one carbon less than 4. A comparison of the NMR spectra of 4 
and 6 confirmed that a methyl group was missing in 6, while a new aromatic proton 
signal was found. The only methyl group attached to an aromatic ring is 13-CH3. 
Therefore, 4 is likely the 12-demethylated derivative of 4. This was supported by the 
HMBC correlations of 12-H at δ 7.53 to C-1 (δ 179.1), C-11 (δ 36.8), C-4a (δ 113.6) 
and C-5a (δ 123.3) (Fig. 24). Thus, the structure of 6 was determined to be 
12-demethyldutomycin. It is a new compound and named as SW91. The carbon and 
proton signals were assigned based on 2D NMR and a comparison with 4, and are 
shown in Tables 7 and 8, respectively. The titer of 6 was determined to be 66.697±1.0 
mg/l. Identification of 6 revealed that DutMT1 is a C-MT that attaches a methyl group 
to C-12.  
 
The disruption plasmid pSW85 was also introduced into the 
dutomycin-producing strain for single crossover to yield S. minoensis NRRL 
B-5482-ΔDutMT2. The correct mutant was confirmed by PCR analysis (Appendix E). 
Sequence analysis predicted that DutMT2 is a putative O-MT. However, HPLC 
analysis of the products of S. minoensis NRRL B-5482-ΔDutMT2 revealed that this 




shown), suggesting that disruption of DutMT2 has shut down the entire dut 
biosynthetic pathway. A similar phenomenon was observed in the previous study on 
the polyketomycin biosynthetic gene cluster, where disruption of PokMT3 also 
abolished the production of any polyketomycin-related products in S. 
diastatochromogenes Tü6028 [11]. DutMT2 shares 95% similarity and 93% identity 
with PokMT3. BLAST analysis also revealed that DutMT2 is homology to TcmN (51% 
identity and 65% similarity), a bifunctional protein that can catalyze the regiospecific 
cyclization and O-methylation of the tetracenomycin [12]. However, DutMT2 (350 aa) 
is much shorter than TcmN (494 aa), and lacks the N-terminal cyclization domain. 
Thus, it is unlikely to participate in the cyclization process. The putative function of 
DutMT2 is the 2-O-MT. However, given the fact that both inactivation of DutMT2 in 
S. minoensis NRRL B-5482 and PokMT3 in S. diastatochromogenes Tü6028 
completely disrupted the corresponding biosynthetic pathway, this type of MT may 
also play an essential role in coordinating the collaborative actions of other 
biosynthetic enzymes.  
5.3.5 Inactivation of DutGT1 and DutGT2 and Characterization of Two New 
Dutomycin Analogs.  
Deoxysugars are frequently present in bioactive molecules such as erythromycin, 
doxorubicin and pradimicin A. Some of these sugar moieties are found to be essential 
in the biological activities. Thus, identification of enzymes responsible for 





Fig. 22 HPLC analysis of the mutants of S. minoensis NRRL-B5482 at 460 nm. Trace 
i: ΔDutMT1; trace ii: ΔDutGT2; trace iii: ΔDutGT1. 
biosynthetic gene cluster, likely involved in introduction of the two sugar moieties to 
the aglycone. In order to distinguish the roles of these two GTs and understand their 
roles, the dutGT2 gene was disrupted using the same single crossover approach. The 
correct ΔDutGT2 mutant was verified by PCR (Appendix E). LC-MS analysis of the 
ethyl acetate of the culture of this mutant revealed that 4 was not produced, but a new 
product 7 accumulated as the major metabolite at 8.2 min (trace ii, Fig. 23). ESI-MS 
spectrum of 4 showed a [M-H]
-
 ion peak at m/z 571.1, indicating that its molecular 
weight is 572. This corresponds to the structure of the aglycone with D-amicetose, 
which is the first sugar moiety in 4. To confirm the structure, 7 was isolated from 1 l 
(i)












of the culture. The purified compound was subjected to 1D and 2D NMR analysis. A 
comparison of the NMR data of 7 and 4 revealed that the second sugar moiety and 
attached C-4" side chain were missing in this new compound, confirming that its 
structure only has the D-amicetose moiety. The spin system of 





COSY spectrum (Fig. 24). Accordingly, the structure of 7 can be established as shown 
in Fig. 19 and was named as SW82. The proton and carbon signals were assigned 
based on the 1D and 2D NMR spectra and a comparison with the data of 4. The 
assigned signals of 7 are listed in Tables 7 and 8, respectively. The titer of 7 was 
determined to be 34.8±0.2 mg/l. Identification of 7 indicated that the function of 

































Fig. 23 Selected 1H-1H COSY and HMBC spectra for 6 and 7. 
The dutGT1 gene was disrupted using the same single crossover approach as well. 
The correct ΔDutGT1 mutant was verified by PCR. LC-MS analysis of the ethyl 
acetate of the culture of this mutant revealed that 4 was not produced, but a major 






 ion peak at m/z 457.0 (Appendix E), suggesting that the molecular 
weight of this compound is 458, which corresponds to the aglycone intermediate in 
dutomycin biosynthesis (Fig.20B). The identity of 8 was confirmed by a comparison 
of the methanolysis product of 4 (Appendix E). DutGT1 is thus confirmed to be 
responsible for introducing the first sugar moiety to the aglycone.  
5.3.6 Minimum inhibition concentration test for dutomycin and its novel derivatives.  
In our initial screening for antibacterial microbial extracts, the ethyl acetate extract 
of S. minoensis NRRL B-5482 was tested against three bacterial strains including 
Gram-negative bacterium E. coli ATCC 25922 and the Gram-positive bacterial strains 
S. aureus (SA) ATCC 25923 and methicillin-resistant S. aureus (MRSA) ATCC 33591. 
This extract was active against SA and MRSA, with MIC values of 500 and 1000 µg/ml, 
respectively. In contrast, it did not show any activity to E. coli (Table 9). After 
purifying compounds 4-7 from the wild type or mutants, we texted these molecules 
against the same panel of bacterial strains. 4 showed significant antibacterial activity 
against the Gram-positive strains, but was not active against the Gram-negative strain 
E. coli. This indicated that 4 specifically targets Gram-positive bacteria. The MIC 
values of 4 for both SA and MRSA were determined to be 0.25 μg/ml, indicating that 
this compound is a highly active antibacterial agent. Anthracyclines are ranked among 
the most effective anticancer drugs ever developed [13]. The first anthracyclines 
discovered were rhodomycin and cinerubicin [14]. Daunorubicin (trade name 




inhibit DNA and RNA synthesis and topoisomerase II enzyme to prevent the rapidly 
growth of cells.[16-18] They were also found to generate free oxygen radicals to 
damage the DNA, protein and cell membranes. [16] Hence, many anthracyclines, 
such as daunorubicin, epirubicin, doxorubicin and aclacinomycin, are used in clinic as 
cancer therapeutics. 4 was previously discovered as an antitumor compound [19] and 
showed strong in vitro cytotoxicity against leukemia P388 cells. [19]  This is the first 
time it was found to be a potent antibacterial agent. Its natural analog polyketomycin 
from other actinomycetes has also shown similar antibacterial activity against 
Gram-positive bacteria. This suggests that this family of anthracyclines represents 
promising lead compounds for new antibiotics development.  
 
The activity of 5-7 was also tested. However, this compound has no obvious 
antibacterial activity and the MICs were 250 µg/ml, which is 1,000-fold higher than 4. 
The MICs of 6 against SA and MRSA were determined to be 0.125 µg/ml, while 
those of 7 were 250 µg/ml (Table 9). These antibacterial testing results of four 
compounds revealed some important SAR information. The presence of the C-4" side 
chain synthesized by the type I PKS DutG in 4 is essential, as removal of this side 
chain led to almost complete loss of the antibacterial activity. The same phenomenon 
was observed for 7, which lacks both the L-axenose moiety and the attached C-4" 
polyketide chain, further confirming that the important role of this functional role. 6 is 




removal of the 13-CH3 can significantly increase the antibacterial activity. The 
activity of 8 was not tested as it lacks the sugar moieties and C-4" side chain, it is 
expected that this compound has no antibacterial activity.  
Table 9. MICs (µg/ml) of 4-7 against three bacterial strains. 
 E. coli SA MRSA 
Crude extract ---- 500 1000 
4 >250 0.25 0.25 
5 >250 250 250 
6 >250 0.125 0.125 
7 >250 250 250 
5.4 Conclusion 
In this study, dutomycin and its precursor POK-MD1 was isolated from 
S.minoensis NRRL B-5482 and structurally characterized. The dutomycin 
biosynthetic gene cluster was identified through genome sequencing and gene 
disruption, and the genes were annotated with putative functions based on sequence 
homology. Three new dutomycin analogs were generated through gene disruption. 
Antibacterial studies on these molecules revealed that the C-4" side chain plays an 
essential role in the biological activity on dutomycin. Removal the CH3-13 
significantly improved the antibacterial activity, suggesting that it is possible to create 
new dutomycin analogs through engineered biosynthesis and the antibacterial activity 
may be further optimized by additional structural modifications to yield novel 
antibiotics to combat Gram-positive pathogens including those developed with 
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CHAPTER 6 SUMMARY AND ENGINEERING VALUE 
 
6.1 Summary  
In summary, this research has engineered polyketide biosynthetic pathways via 
two different approaches to make valuable bioactive molecules. Through heterologous 
expression, we built a very flexible yet efficient biosynthetic platform for the 
production of various plant natural products in E. coli. Enzymes from different 
sources were used as biosynthetic bricks that can be rationally recombined as legos 
for desired products. A variety of bioactive molecules naturally from plants have been 
produced in engineered E. coli strains within 2-3 days. Manipulation of these 
constructed pathways by removal or addition of biosynthetic enzymes led to novel 
“unnatural” molecules. A visible reporter assay was designed to facilitate the 
screening of efficient PALs, which are involved in the first biosynthetic steps of many 
plant phenylpropanoids. In addition to construction of artificial pathways in 
heterologous hosts, natural product biosynthetic pathways can also be modified 
through gene disruption in the original producing strain to yield new bioactive 
compounds. The biosynthetic gene cluster of dutomycin, a natural antibacterial and 
anticancer molecule, was discovered through genome sequencing and targeted gene 
disruption. Several enzymes in this pathway were functionally characterized. 




much higher antibacterial activity against Staphylococcus aureus and 
methicillin-resistant Staphylococcus aureus than the original natural product.  
6.2 Engineering value  
6.2.1 Engineered production of hydroxycinnamic acids and stilbenoids in E. coli 
Hydroxycinnamic acids (HCAs) are important phytochemicals possessing 
significant biological properties such as management of oxidative stress-related 
diseases. Stilbenoids, containing a C6-C2-C6 core structure, are a class of plant 
secondary metabolites often involved in injury therapy when the plant is threatened by 
bacteria or fungi. These molecules have shown a variety of biological properties, such 
as antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory and anti-aging 
activities. In Chapter 2, we produced resveratrol from L-tyrosine in a yield of 114 mg/l 
by engineering an artificial biosynthetic pathway into E. coli and optimizing the 
fermentation conditions. This yield is much higher than those previously reported. 
Furthermore, piceatannol is a hydroxylated derivative with better biological activities, 
but the application of this compound is limited by low yield in plants, which explains 
the high price of this compound. In Chapter 2, we made it possible to produce 
piceatannol in the E. coli system with the platform we established. The engineered E. 
coli strain that harbors C3H can efficiently convert the relatively inexpensive 




days. This research thus provides a new method for large scale production of 
piceatannol.  
  
6.2.2 Engineered biosynthesis of curcuminoids and two “unnatural” molecules in E. 
coli. 
Curcuminoids are used as food spice (curry) and food coloring agent (E100). In 
addition, they are the major bioactive components in turmeric that have been used in 
Asian traditional medicine for centuries. Curcuminoids are well-known for their 
anti-tumor, anti-oxidant, anti-inflammatory, anti-allergic, and hepatoprotective 
activities. In Chapter 3, we modified the platform established in Chapter 2 with more 
genes from plants and successfully produced three different natural curcuminoids. 
While curcuminoids are present as a mixture in nature, this method allowed the 
production of a single curcuminoid in E. coli. That simplifies the downstream 
processing and purification of the three different curcuminoids that have similar 
physical and chemical properties. Also in Chapter 3, two novel unnatural compounds 
were generated by E. coli via genetic modification of the pathways. This 
demonstrated a highly efficient combinatorial biosynthesis approach to creating 
various plant phenylpropanoids in E. coli.      





Phenylalanine ammonia-lyase (PAL) is an important enzyme that links primary 
metabolism to secondary metabolism. Its efficiency is often a critical factor that 
affects the overall flux of a related metabolic pathway, the titer of the final products, 
and the efficacy of PAL-based therapies. In Chapter 4, a novel and efficient visible 
reporter assay for screening of PAL efficiency in E. coli was established based on the 
curcuminoid polyketide biosynthetic pathway. Taking advantage of the yellow color 
of the product, a microplate-based assay was designed to measure the titer of 
dicinnamoylmethane, which was validated by HPLC analysis. The different titers of 
the product reflect the overall performance (expression level and enzymatic activity) 
of the individual PALs in E. coli. This provides a convenient way to screen efficient 
PALs for various pathways including plant phenylpropanoid biosynthetic pathways 
studied in this dissertation.  
6.2.4 Biosynthesis and antibacterial activity of dutomycin and analogs 
In this study, dutomycin and its precursor POK-MD1 were isolated from S. 
minoensis NRRL B-5482 and structurally characterized. The dutomycin biosynthetic 
gene cluster was identified through genome sequencing and gene disruption. The 
genes were annotated with putative functions based on sequence homology. Three 
new dutomycin analogs were generated through gene disruption. Antibacterial studies 
on these molecules revealed that the C-4" side chain plays an essential role in the 
biological activity on dutomycin. Removal of the CH3-13 significantly improved the 




through engineered biosynthesis. Antibacterial activity may be further optimized by 
additional structural modifications to yield novel antibiotics for combating 
Gram-positive pathogens, including those developed with drug-resistance. All these 
studies open the door for further engineering, bioactivity screening, improvement, and 







































































































































































H NMR (DMSO-d6 ) δ 9.53 (1H, s), 9.18 (2H, s), 7.39 (2H, d, J = 8.6), 
6.94 (1H, d, J = 16.5), 6.80 (1H, d, J = 16.5), 6.75 (2H, d, J = 8.6), 6.38 (2H, d, J = 
1.3), 6.12 (1H, d, J = 1.3). 
 
Fig.B1. ESI-MS analyses of hydroxycinnamic acids production. a. ESI-MS (-) 
spectrum of p-coumaric acid production from tyrosine; b. ESI-MS (-) spectrum of 




production from tyrosine; d. ESI-MS (-) spectrum of cinnamic acid production from 
phenylalanine. 
 
Fig.B2. LC-MS analyses of resveratrol production. a. ESI-MS (+) spectrum of 
resveratrol production from tyrosine; b. ESI-MS (-) spectrum of resveratrol 





Fig. B3. LC-MS analyses of natural stilbenoids production. a. ESI-MS (-) spectrum of 
piceatannol production from tyrosine; b. UV spectrum of piceatannol production from 
tyrosine; c. ESI-MS (-) spectrum of pinosylvin production from phenylalanine; d. UV 













































H NMR (acetone-d6) δ 7.60 (2H, d, J = 15.4), 7.33 (2H, d, J = 2.0), 7.17 




H NMR (CD3OD) δ 7.38 (2H, d, J = 8.6), 7.27 (1H, d, J = 





H NMR (CD3OD) δ7.50 (2H, d, J = 15.7), 7.07 (2H, brs), 
















 Table D1. 
1
H (300 MHz) and 
13
C (75 MHz) NMR data for 2 (acetone-d6, δ in 






1 6.17 (1H, s) 103.3 
2 --- 182.9 
3 6.90 (1H, d, J = 16.0) 129.1 
4 7.70 (1H, d, J = 15.9) 136.1 
5 --- 123.9 
6 --- 163.3 
7 7.22 (1H, dd, J = 2.5, 8.2) 116.8 
8 7.75–7.78 (1H, m) 117.1 
9 7.28 (1H, t, J = 7.7) 125.8 
10 7.81–7.83 (1H, m) 131.9 
2' --- 184.9 
3' 6.94 (1H, d, J = 16.0) 129.2 
4' 7.77 (1H, d, J = 16.1) 140.7 
5' --- 124.2 
6' 7.70 (1H, dd, J = 2.5, 7.7) 130.6 
7' 7.41–7.44 (1H, m) 130.7 
8' 7.37–7.41(1H, m) 129.9 
9' 7.41–7.44 (1H, m) 130.7 





Table D2. Time course analysis of the production of 1 by different PALs through 
UV-Vis microplate reader and HPLC analyses. The yields were calculated 
from three independent experiments and are presented as mean ± SD (g/l). 
Method Time PAL1 PAL3 PAL4 
HPLC 
12 h 0.087±0.007 0.011±0.001 0.014±0.001 
24 h 0.201±0.005 0.032±0.001 0.036±0.004 
36 h 0.233±0.005 0.038±0.006 0.044±0.004 
48 h 0.271±0.018 0.047±0.003 0.082±0.008 
60 h 0.343±0.012 0.073±0.019 0.092±0.005 




12 h 0.053±0.003 0.012±0.001 0.012±0.001 
24 h 0.159±0.005 0.022±0.001 0.046±0.004 
36 h 0.212±0.004 0.042±0.007 0.049±0.004 
48 h 0.248±0.009 0.053±0.003 0.078±0.008 
60 h 0.342±0.003 0.072±0.004 0.082±0.002 












Fig. E1. Typical UV absorptions of anthracycline antibiotics. 
 












Fig. E2 The ESI-MS analysis of 4 -8 
 

































































Table E1. Primers used in this study.* 
Primer Sequence 
Type II KS-F 5’-TSGCSTGCTTCGAYGCSATC-3’ 







DutGT1-F 5’- AAAAGCTTGATCCGCGCGCTGTA -3’ 
DutGT1-R 5’- AATCTAGAATCTCTGTGCAGATCGGTGA -3’ 
DutKS-Check1 5’-GTCTCCACGGGCTGTACCTC-3’ 
DutKS-Check2 5’-ATCAGCCGGCTGGGCAGATG-3’ 
DutMT1-Check1 5’- ATGACAGCTCCCGCTCTCGAA -3’ 
DutMT1-Check2 5’- ATTTATTGGCGTCATCAGGTTGT -3’ 
DutMT2-Check1 5’- AGCCTCCGAAGAGGCTCGG -3’ 




DutGT1-Check2 5’- TGACGATGTCGATGGCCAA-3’ 
M13-47 5’-CGCCAGGGTTTTCCCAGTCACGAC-3’ 
RM-V 5’-GAGCGGATAACAATTTCACACAGG-3’ 





















Fig. E8 The identity of 8 was confirmed by a comparison of the methanolysis product 
of 4. 
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Engineering design components in Chapters 2 and 3: Biosynthetic enzymes from 
different sources were used to design artificial metabolic pathways to produce various 
molecules. A libray of biosynthetic bricks was constructed and various biosynthetic 
pathways were assembled in E. coli using these biosynthetic bricks to generate four 
phenylpropanoid acids (cinnamic acid, p-coumaric acid, caffeic acid, and ferulic acid), 
three bioactive natural stilbenoids (resveratrol, piceatannol and pinosylvin), and three 
natural curcuminoids (curcumin, bisdemethoxycurcumin and dicinnamoylmethane) 
The yields were improved by optimizing the substrate concentrations.  
 
Engineering design components in Chapter 4: Taking advantage of the yellow 
color of dicinnamoylmethane, a novel and visible microplate-based assay was 
designed for screening highly efficient PALs. This method requires remarkably 
smaller volumes, lower costs and shorter time compared to traditional analytic 
methods. This assay can be widely used in the industry or academia to search novel 
PALs for production improvement or therapeutics development.  
 
Engineering design components in Chapter 5: The dutomycin biosynthetic gene 
cluster was discovered by genome sequencing and confirmed by gene disruption. 
Three new dutomycin analogs were generated by manipulating the pathway. This 
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phenylpropanoid acids, three bioactive natural stilbenoids, three 
natural curcuminoids and two unnatural compounds.  
o Established a novel and efficient visible reporter assay for screening 





National Institutes of Health grants  
o Discovered the biosynthetic gene cluster for the antibacterial 
compound dutomycin.  
o Confirmed the involvement of this gene cluster in dutomycin 
biosynthesis and created a series of new molecules by rationally 
modifying the biosynthetic pathway.  
o Created a new demethylated analog of dutomycin that has much 
higher antibacterial activity against Staphylococcus aureus and 
methicillin-resistant Staphylococcus aureus.  
Lab Manager & Safety Officer                                                           
May 2014 –present 
Research Laboratory for Metabolic Engineering  
Utah State University, Logan, UT  
o Check inventory and inspect lab safety. 
Teaching Assistant   Jan 2013 – May 2013 
Department of Biological Engineering  
Utah State University, Logan, UT 
o Teach and guided the lab session of Metabolic Engineering course.  
Undergraduate Research Assistant  Sep 2009 - June 2011 
College of Life Science 
Nanjing Normal University Nanjing, China 
Biotransformation of puerarin  
o Modified puerarin by wild type strain biotransformation. 
SKILLS 
 Molecular Biology 
Plasimid construction, PCR, Electrophoresis, DNA Purification, RNA 
extraction, Fusion Expression , SDS-PAGE , Western Blot Analysis, 
q-PCR, primer design and gene sequencing analysis. 
Instrument Analysis  
HPLC, LC-MS, GC-MS, NMR, TLC, FT-IR. 
Tools  
Agilent chemistry station, Endnote, Primer Premier, DNAMAN, Origin 
Lab. 
Computer Skills 
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solvent-tolerant strain of Lysinibacillus fusiformis. Enzyme and 
Microbial Technology 57, 42-47.    IF=2.966 
5. Mei, J.,# Wang, L.,# Wang, S., Zhan, J.* (2014): Synthesis of two new 
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Microbiology and Biotechnology 40(1), 159–168  IF=2.505 
8. Wang, S., Zhang, S., Zhou, T., Zhan, J.* (2013): Three new resorcylic 
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Chemistry Letters 23(21), 5806–5809. IF=2.331  
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in Saccharomyces cerevisiae. Metabolic Engineering 18, 60–68.    
IF=8.258 
10. Yu, D.,# Xu, F.,# Zhang, S.,# Shao, L., Wang, S., Zhan, J.* (2013): 
Characterization of a methyltransferase involved in herboxidiene 
biosynthesis. Bioorganic & Medicinal Chemistry Letters 23(20), 
5667–5670.  IF=2.331 
11. Liu, G., Sun, L., Wang, S., Chen, C., Guo, T., Ji, Y & Yuan, S. * (2011): 
Hydroxylation modification and free radical scavenging activity of 
puerarin-7-O-fructoside. Folia Microbiologica, 56(4), 305-331.    
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the conversion of puerarin from puerarin-7-O-glucoside to 
puerarin-7-O-fructoside. Applied Microbiology and Biotechnology, 
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PRESENTATIONS 
 1. “Engineered biosynthesis of plant polyphenols in Escherichia coli,” 
Institute of Biological Engineering Annual Conference, March 2014.  
2. “Design and application of an in vivo reporter assay for phenylalanine 
ammonia-lyase,” Hansen Life Science Retreat, September 2013. 
3. “Towards engineered biosynthesis of curcuminoids in lactic acid 
bacteria,” Institute of Biological Engineering western regional 
conference, October 2013. 
4. “Efficient glycosylation of puerarin by an organic solvent-tolerant strain 
of Lysinibacillus fusiformis,” Intermountain Graduate Research 
Symposium, April 2012. 
PROFESSIONAL MEMBERSHIP 
 Institute of Biological Engineering student membership 
GRANTS AND AWARDS 
 Outstanding Engineering Graduate Scholar of Utah State University                               
2015 
Second prize of podium presentation of IBE western regional conference                       
2012  
RELEVANT COURSES 
  Metabolic Engineering  
 Synthetic Biological Engineering 
 Biology System Modeling  
 Natural Product Chemistry  
 Biochemistry Engineering 
 Supervised Teaching    
 
 
